

Loews Miami Beach Hotel
May 29–June 1, 2018



ASCP 2018 ANNUAL MEETING:
Treatment of Psychiatric Illness
Across the Lifespan



ASCP

AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

www.ASCPMeeting.org



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY



Dear Colleagues,

Welcome to Miami Beach!

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am delighted to welcome you to our outstanding annual scientific meeting. I want to thank both the Program Committee and the Steering Committee for their labors to set the stage for what I hope you will agree will be one of the best ASCP meetings ever.

This year's meeting includes not only a very stimulating joint workshop with the American Foundation for Suicide Prevention (AFSP) but also the 26th edition of our very successful New Investigators' Program. For the second year, we will have an Early Career Luncheon with panelists from diverse career trajectories and will have tables set aside for early career attendees at each lunch session to facilitate networking. Our meeting has something for everyone.

We hope that you'll agree that our meeting offers something for virtually everyone interested in clinical psychopharmacology. Although we hope that you will find some time to enjoy the beach and the sights and sounds of South Beach, we also hope that you'll be able to attend our annual Federal Agency Directors Plenary and truly unique Regulatory Session that traditionally serves as the closing session of our meeting.

The ASCP is committed to finding and testing new therapies for our patients. We want to advance not only the field of psychopharmacology but treatment research in general. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials. I am sure that we will see presentations and posters at this meeting that will become important methods for caring for our patients in the future.

Our society has taken on a new responsibility in the past year and is actively becoming one of the places that legislators, federal agencies, and other groups interested in public policy turn to for advice on therapy and research questions about brain diseases. As the experts in the field we have a responsibility to our patients and society to weigh in on these important issues. Please contact our colleagues at Parthenon Management Group if you have an interest in this or any other ASCP activities or committees.

I hope you have a wonderful time learning, presenting, and seeing old and new friends at our annual meeting.

Michael E. Thase, MD
President
American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2018 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

- **2018 Program Highlights**
 - **Tuesday, May 29th**
 - Conference Opening
 - Early Career Luncheon (RSVP Only)
 - Pharma Pipeline: 11 presentations of Phase 1 and Phase 2 developments
 - Individual Research Reports
 - **Wednesday, May 30th**
 - 19th Annual Fun Run/Walk
 - Regulatory Plenary: Autism Spectrum Disorder
 - ASCP Lifetime Awardee Talk
 - Poster Session I
 - ASCP Reception
 - **Thursday, May 31st**
 - Keynote Plenary: Treatment of Psychiatric Illness Across the Lifespan
 - Federal Agency Directors Plenary
 - Poster Session II
 - Clinical Updates in Psychopharmacology
 - **Friday, June 1st**
 - Regulatory Wrap-Up Plenary with FDA regulators
 - **Throughout the meeting**
 - NIMH, NIDA, NIAAA, and FDA panels
 - **The New Investigator Program**
 - A closed workshop for 20 New Investigators and informal breakfast sessions.
 - **Workshops:** 2-hour intensive interactive sessions focused on problems and solutions
 - Wednesday and Thursday Afternoons
 - ***Clinical Track*** – Sessions focused on topics of immediate clinical relevance
- **Organization**
 - The meeting is sponsored by the American Society for Clinical Psychopharmacology (ASCP).
 - The Steering Committee organizes the meeting.
 - The Program Committee evaluates submitted proposals and develops program innovations.
 - Federal agency collaborations:
 - DoD - Department of Defense
 - NIAAA - National Institute on Alcohol Abuse and Alcoholism
 - NIDA - National Institute of Drug Abuse
 - NIMH - National Institute of Mental Health
 - VA - U.S. Department of Veterans Affairs
 - Regulatory agency collaborations:
 - Food and Drug Administration (FDA)
 - Center for Drug Evaluation and Research (CDER)
 - European Medicines Agency (EMA)
 - Italian Medicines Agency (AIFA)
 - Parthenon Management Group organizes the ASCP Annual Meeting.
- **And remember**
 - The Fun Run/Walk is Wednesday, May 30th at 6:30 a.m. All are welcome to join!
 - The ASCP Reception is Wednesday, May 30th from 6:00 p.m. – 7:00 p.m.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.


Best Regards,



Marlene Freeman, M.D.
Steering Committee Co-chair



Anita Clayton, M.D.
Program Committee Co-chair




John Newcomer, M.D.
Steering Committee Co-chair




Holly A. Swartz, M.D.
Program Committee Co-chair

Loews Miami Beach Hotel

Second Level




Third Level



Award Winners and Featured Speakers	5
Acknowledgements	15
Meeting Announcements.....	21
Monday, May 28, 2018	25
Tuesday, May 29, 2018.....	29
Wednesday, May 30, 2018	45
Thursday, May 31, 2018	57
Friday, June 1, 2018.....	67
Poster Session I.....	73
Poster Session II.....	84
Author Index	95

**DISCLOSURES FOR ALL ASCP PRESENTERS
CAN BE VIEWED AT WWW.ASCPMEETING.ORG**

Recipient of the Donald Klein Lifetime Achievement Award



Phil Skolnick, Ph.D.
Opiant Pharmaceuticals

Dr. Skolnick was appointed Chief Scientific Officer at Opiant Pharmaceuticals, Inc. in 2017. Prior to joining Opiant, he was the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017). Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He served as a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). His 25-year career at the NIH intramural research program began with a postdoctoral fellowship in the laboratory of John W. Daly (1972-1977), and ended as Chief, Laboratory of Neuroscience, NIDDK (1986-1997). Dr. Skolnick has received multiple honors and awards, including the A.E. Bennett Award in Biological Psychiatry, an Anna Monika Prize, and the Experimental Therapeutics Prize from the American Society of Pharmacology & Experimental Therapeutics. He has also twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has co-authored more than 580 articles. The Institute of Scientific Information (ISI) has named him to the elite group of “Highly Cited” authors.

Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award



Philip Gerretsen, FRCPC, M.D.

Centre for Addiction and Mental Health, University of Toronto

Nominated for: *Anosognosia is an Independent Predictor of Conversion from MCI to AD and is Associated with Reduced Brain Metabolism*

Gerretsen P, Chung JK, Shah P, Plitman E, Iwata Y, Caravaggio F, Nakajima S, Pollock BG, Graff-Guerrero A; Alzheimer's Disease Neuroimaging Initiative.

Dr. Philip Gerretsen is a clinician-scientist in the Campbell Family Mental Health Research Institute and Geriatric Mental Health Services at the Centre for Addiction and Mental Health. He is an Assistant Professor in the Department of Psychiatry, Faculty of Medicine at the University of Toronto.

Impaired illness awareness is a well-recognized, but understudied phenomenon that contributes to minimization and denial of the need for treatment with devastating clinical and social consequences. The focus of Dr. Gerretsen's research has been the identification of the neural correlates of impaired illness awareness in schizophrenia primarily through structural and functional neuroimaging. The results have provided prospective biomarkers and regional brain targets for intervention psychotherapeutically and with noninvasive neurostimulation, such as transcranial direct current, magnetic and vestibular stimulation. The next step is to extend this work to other neuropsychiatric and medical conditions that can feature impaired illness awareness, including neurodegenerative disorders, obesity, hypertension, diabetes, and addictions. The relevance of this work lies in the potential to alter individuals' attitude toward their illness and treatment. This would lead ultimately to an improvement in individuals' capacity for illness recognition and engagement in treatment, which would, in turn, have a significant impact on disease management.



New Investigator Awardees

Teddy Akiki, M.D.

Yale University

Katie Burkhouse, Ph.D.

University of Illinois at Chicago

Araba Chintoh, M.D., Ph.D.

Centre for Addiction and Mental Health

Sabrina Correa da Costa, M.D.

University of Texas Health Science Center at Houston

Zhi-De Deng, Ph.D.

National Institute of Mental Health

Jennifer Evans, Ph.D.

National Institute of Mental Health

Bharathi Gadad, Ph.D.

University of Texas Southwestern Medical Center at Dallas

Jessica Gannon, M.D.

University of Pittsburgh School of Medicine

Rebecca Hendrickson, M.D.

VA Puget Sound Health Care System

Carla Nasca, Ph.D.

The Rockefeller University

Andrew Olagunju, M.D.

The University of Adelaide

Michelle Patriquin, Ph.D.

Baylor College of Medicine

Stephanie Phan, Pharm.D.

University of Georgia College of Pharmacy

Albert Powers, M.D., Ph.D.

CT Mental Health Center, Ribicoff Labs, Yale University

Steven Proctor, Ph.D.

Albizu University

Naji Salloum, M.D.

Harvard Medical School/
Massachusetts General Hospital

Charles South, Ph.D.

UTSW Medical Center Dallas

Christine Ulbricht, M.P.H., Ph.D.

University of Massachusetts Medical School

Anthony Zannas, M.D., M.Sc., Ph.D.

Max-Planck Institute of Psychiatry

Zachary Zuschlag, D.O.

James A. Haley Veterans Hospital

2017 ASCP Early Career Research Awardee

Yash Joshi, M.D., Ph.D.

University of California, San Diego

Nominated for: *Effect of Anticholinergic Medication Burden on Cognitive Training: A Pharmacology-Guided Precision Medicine Approach for Reducing Neurocognitive Impairment in Psychosis*

See Dr. Joshi's poster on Thursday, May 31, 2018 at Poster #T43.

Regulatory Plenary: Autism Spectrum Disorder**Wednesday, May 30th from 8:30 a.m. – 10:00 a.m.**

Tiffany Farchione, M.D.
US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center and was on the faculty of the University of Pittsburgh.

As the Deputy Director in the Division of Psychiatry Products at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.



Valentina Mantua, M.D., Ph.D.
Italian Medicines Agency (AIFA)

Valentina Mantua is a medical doctor and a psychiatrist with an extensive clinical experience in the field of psychosis and affective disorders both at the Maudsley NHS Trust in London and University Hospital in Pisa, Italy, where she also obtained a Ph.D. in Neurobiology of Affective Disorders.

She joined the regulatory world in 2012 as expert CNS assessor at the Italian Medicines Agency (AIFA) and she is currently Italian member of the Central Nervous System Working Party on (CNSWP) at the European Medicines Agency (EMA). She is also the Italian representative at the EU-Innovation Network, supporting innovation in drug development both at a national and European level.

Keynote Plenary: Treatment of Psychiatric Illness Across the Lifespan

Thursday, May 31st from 8:15 a.m. - 9:45 a.m.



Sandra Comer, Ph.D.
Columbia University & New York State Psychiatric Institute

Dr. Sandra Comer is Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University, and Research Scientist VI at the New York State Psychiatric Institute. She received her B.S. at Vanderbilt University and Ph.D. at the University of Michigan for her research on the effects of abused drugs using preclinical models. Dr. Comer's research focus at Columbia University has been on the clinical development and testing of novel approaches to the treatment of opioid use disorder (OUD), including the influence of sex differences and hormonal influences on responses to pain and opioid medications, the role of inflammation on opioid-mediated effects, and the ability of sustained-release medications to alter the subjective and reinforcing effects of opioids. She currently directs a very active laboratory to evaluate medications to treat OUD, as well as combined opioid and alcohol use disorders. In addition, she is conducting a large, prospective, longitudinal study to evaluate ways to maximize the use and effectiveness of naloxone by opioid users to reverse opioid overdose. Dr. Comer is also evaluating the comparative abuse liability of several commonly prescribed pain medications using laboratory models of drug self-administration in humans.

She served as a regular member of the National Institutes of Health Biobehavioral Regulation, Learning and Ethology (BRLE) study section and numerous ad hoc NIH grant review committees. She was a voting member of the Institutional Review Board of the New York State Psychiatric Institute and of the Faculty Council of the Faculty of Medicine. For several years, Dr. Comer served as Program Chair of the College on Problems of Drug Dependence, the longest standing scholarly society in the United States that is devoted to issues surrounding substance use disorders. She was also President of CPDD and currently is serving as the Public Policy Officer for CPDD. Dr. Comer recently joined the Expert Advisory Panel on Drug Dependence for the World Health Organization and is the author or co-author of more than 140 papers, chapters, and books dealing with several aspects of substance abuse.



Helen Mayberg, M.D.
Icahn School of Medicine At Mount Sinai

Helen Mayberg, M.D. is Professor of Neurology, Neurosurgery, Psychiatry and Neuroscience, and the Mount Sinai Professor in Neurotherapeutics at the Icahn School of Medicine. She was recently recruited to New York after 14 years at Emory University in Atlanta where she was Professor of Psychiatry, Neurology and Radiology and the Dorothy Fuqua Chair in Psychiatry Neuroimaging and Therapeutics. Her research has characterized neural systems mediating major depression and its recovery, defined imaging-based illness subtypes to optimize treatment selection, and introduced the first use of deep brain stimulation for treatment resistant patients. Dr. Mayberg received a BA in Psychobiology from UCLA and a MD from University of Southern California, and then completed her neurology residency at the Neurological Institute of New York, and fellowship training in nuclear medicine at Johns Hopkins. She is a member of the National Academy of Medicine, the National Academy of Arts and Sciences, and the National Academy of Inventors, and has authored more than 200 publications, and participates in a wide variety of advisory and scientific activities across multiple fields in neuroscience.



J. John Mann, M.D.
Columbia University

J. John Mann, M.D., is The Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) and Vice Chair for Research in the Department of Psychiatry at Columbia University. He is Director of Research and Director of Molecular Imaging and the Neuropathology Division at the New York State Psychiatric Institute.

Dr. Mann is trained in Psychiatry and Internal Medicine and has a Doctorate in Neurochemistry. His research employs functional brain imaging, neurochemistry and molecular genetics to probe the causes of depression and suicide. Dr. Mann is the Director of the NIMH Conte Center for the Neuroscience of Mental Disorders, and Past President of the International Academy of Suicide Research.

Dr. Mann has published 458 papers and edited 10 books on the subjects of the biology and treatment of mood disorders, suicidal behavior and other psychiatric disorders. In private practice he specializes in the treatment of mood disorders.

Federal Agency Directors Plenary

Thursday, May 31st from 10:00 a.m. – 12:30 p.m.



Lorenzo Leggio, M.D., Ph.D., M.Sc.
National Institute on Alcohol Abuse and Alcoholism

Dr. Lorenzo Leggio received his M.D. and Ph.D. from the Catholic University of Rome and 'Agostino Gemelli' hospital, where he also completed residency and received Board Certification in Internal Medicine. He also received a Masters in 'Alcohol-related diseases and problems' from the University of Florence. He was a visiting research

associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, Dr. Leggio joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown University Center for Alcohol and Addiction Studies (CAAS). As a Principal Investigator at Brown University, Dr. Leggio received extramural research funding from NIAAA and NIDA, as well as from the European Foundation for Alcohol Research, Brown University CAAS, ABMRF/The Foundation for Alcohol Research, and the Brain & Behavior Research Foundation (formerly NARSAD). In June 2012, Dr. Leggio joined the NIH Intramural Research Program (IRP) in Bethesda, MD, as a Clinical Investigator and Chief of the Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, a NIAAA laboratory (joint with NIDA). Clinically, Dr. Leggio serves as a NIH Senior Attending Medical Staff. Additionally, he is a Professor (Adjunct) at the Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University. Dr. Leggio's clinical research has been primarily focused on the treatment of alcohol use disorder, with a special emphasis on the role of feeding-related as well as GABAergic pathways; and on the medical consequences of alcohol use disorder, with a special emphasis on alcoholic liver disease. Dr. Leggio's lab has pioneered clinical research on the role of neuroendocrine signaling in alcohol-seeking behaviors via human laboratory studies. He has authored or co-authored over 140 peer-reviewed manuscripts and has served as a regular reviewer for many journals, reviewer for NIH study sections and other U.S. and international funding agencies and member of an FDA Advisory Board. He currently serves on the editorial board of several addiction-related journals and is a member of the Advisory Council of the Peter G. Dodge Foundation. Dr. Leggio has served as Chair (Medical/Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee and is a member of the American College of Neuropsychopharmacology. Among other awards, he received the 2008 European Society for Biomedical Research on Alcoholism (ESBRA) Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, the 2016 RSA Early Career Investigator Award, and the 2018 NIAAA Scientific Achievement Award.



Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Dr. Montoya is a psychiatrist and epidemiologist who specializes in the development of therapeutics for Substance Use Disorders (SUDs). He provides programmatic oversight for grants and contracts in DTMC, and manages activities and resources of the Division involved in the research of new therapeutics and the medical consequences of SUDs.

He also provides medical oversight to grants and contracts, as well as supports NIDA's implementation of NIH wide policies for the Clinical Trials Stewardship Initiative. He leads NIDA's marijuana medications development initiative and the recently published funding opportunity for the development of medications to prevent opioid use disorders and overdose, which is part of the NIH's Public Private Partnership to combat the opioid use crisis. He collaborates with the IRP in research projects, with NIDA's International Office in the Latin American Initiative, and is a member of several scientific interest workgroups. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. He joined NIDA in December 1999.



Shelli Avenevoli, Ph.D.
National Institute of Mental Health

Shelli Avenevoli, Ph.D., is the Deputy Director for the National Institute of Mental Health, the lead Federal agency for research on mental illness, with a budget of \$1.4 billion and a staff of over 1,000. NIMH seeks to transform the understanding and treatment of mental illnesses through

basic and clinical research, paving the way for prevention, recovery, and cure.

Dr. Avenevoli joined NIMH as a staff scientist in 2001, in the Section on Development Genetic Epidemiology of the Mood and Anxiety Disorders Program. In 2005, she moved to the NIMH extramural program to lead funding portfolios focused on developmental trajectories of mental disorders. She has participated in and led a number of key NIMH and NIH efforts, among them the revision of NIMH's Strategic Plan, re-defining the institute's approach to supporting research in neurodevelopment and bipolar disorder, development of a 2025 NIMH suicide research plan, the Adolescent Brain and Cognitive Development study, and the NIH ECHO and All of Us programs.

Dr. Avenevoli received her Ph.D. in Developmental Psychology from Temple University and completed an NIMH postdoctoral fellowship in psychiatric epidemiology at Yale University School of Medicine.



Lori Davis, M.D.
Tuscaloosa VA Medical Center

Dr. Lori Davis is the Associate Chief of Staff for Research at the Tuscaloosa VA Medical Center. She has been conducting clinical trials in the treatment of PTSD, schizophrenia, addictions, and mood disorders in VA settings over the past 25 years. She has worked closely with the VA Office of Research and Development as a member of the committee of experts for the VA PTSD Psychopharmacology Initiative. She was also a member of the recent workgroup that updated the VA-DoD PTSD treatment guidelines (2017).



Ronald L. Hoover, Ph.D.
Military Operational Medicine Research Program

Ronald L. Hoover, Ph.D., is the Psychiatry and Clinical Psychology Health Portfolio Manager within the Military Operational Medicine Research Program at the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland. The primary focus of this research portfolio includes understanding, preventing and treating Post-Traumatic Stress Disorder (PTSD). Other funded clinical research topics address common psychological and behavioral co-morbidities of PTSD to include depression, substance abuse, sleep issues, anger, and the development of screening and diagnostic biomarkers for PTSD. Treatment research spans both psychotherapeutic and pharmacologic care approaches, with particular emphasis on demonstrating efficacy of use for a military population with combat-related traumatic exposures. The limited number of FDA approved medications for PTSD, along with the difficulty of successfully delivering psychotherapy, brings into sharp focus the need for additional research in psychopharmacologic approaches to prevention and care.

Dr. Hoover is a licensed clinical psychologist and obtained a B.A. in Biology from Wittenberg University, Springfield, Ohio. His Ph.D. in Clinical Psychology was awarded from the University of Cincinnati, Cincinnati, Ohio. Prior to his current position Dr. Hoover was a clinician at the Chillicothe, Ohio VA. Dr. Hoover is also a retired CAPT from the Naval Reserve Intelligence Program.

Regulatory Wrap-Up**Friday, June 1st from 10:15 a.m. – 11:45 a.m.****Tiffany Farchione, M.D.****US Food and Drug Administration***See previous bio***Mitchell Mathis, M.D.****US Food and Drug Administration**

Mitchell Mathis, M.D., is the Director, Division of Psychiatry Products (DPP), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA). He and his team are responsible for regulating psychiatric medications used in the United States from first-in-human trials, through Phase 2 and Phase 3 of development, to marketing approval, and beyond (post-approval drug monitoring). FDA has a large role in determining which medications are developed for which indications in what populations, and the Division of Psychiatry Products derives the policies and endorses the clinical trial designs used to evaluate psychiatric medications for safety and efficacy—trials used to support US marketing approval of new medications. Dr. Mathis is trained in Psychiatry and Family Medicine and has practiced psychiatry in his community since 2002.

Valentina Mantua, M.D., Ph.D.**Italian Medicines Agency (AIFA)***See previous bio*

Steering Committee Chairs



Marlene Freeman, M.D.



John Newcomer, M.D.

Program Chairs




Anita Clayton, M.D.



Holly A. Swartz, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Christopher Sarampote, Ph.D.

Steering Committee Members

Ross Baker, Ph.D.
Otsuka Pharmaceuticals

- ★ Anita Clayton, M.D.
University of Virginia

Lee Cohen, M.D.
Massachusetts General Hospital

- ★ Lori Davis, M.D.
Tuscaloosa VA Medical Center

Bryan Dirks, M.D.
Acadia Pharmaceuticals

Elliot Ehrich, M.D.
Alkermes Pharmaceuticals

- ★ Tiffany Farchione, M.D.
US Food and Drug Administration

Susan Kornstein, M.D.
Virginia Commonwealth University

David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

Raye Litten, Ph.D.
National Institute of Alcohol Abuse and Alcoholism

Antony Loebel, M.D.
Sunovion Pharmaceuticals

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

- ★ Francisco Moreno, M.D.
University of Arizona

Stephanie O'Malley, Ph.D.
Yale University School of Medicine

Joseph Palumbo, M.D.
Mitsubishi Tanabe Pharma Development America

Luca Pani, M.D.
European Medicines Agency

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

Steering Committee Members (continued)

Mark Pollack, M.D.
Rush University Medical Center

Mark H. Rapaport, M.D.
Emory University School of Medicine

- ★ Holly Swartz, M.D.
University of Pittsburgh School of Medicine
- ★ Madhukar Trivedi, M.D.
University of Texas Southwestern Medical Center

Program Committee

Scott Aaronson, M.D.
Sheppard Pratt Health Systems

Mohammed Ahmed, M.D.
University of California, San Diego

Amit Anand, M.D.
Cleveland Clinic Lerner School of Medicine of Case Western University

Pratik Bahekar, M.D.
SUNY Downstate Medical Center

Anahita Bassir Nia, M.D.*
Icahn School of Medicine

- ★ Isabelle Bauer, Ph.D.
University of Texas Health Science Center at Houston
- ★ Crystal Clark, M.D.
Northwestern University
- Lawrence Cohen, Pharm.D.
University of North Texas Health Science Center
- Lynn Crismon, Pharm.D.
The University of Texas at Austin
- Larry Culpepper, M.D., M.P.H.
Boston University
- ★ Cristina Cusin, M.D.
Massachusetts General Hospital

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

Program Committee (continued)

Maurizio Fava, M.D.
Massachusetts General Hospital

Ahmad Hameed, M.D.
Pennsylvania State College of Medicine

Usman Hameed, M.D.
Penn State Hersey Medical Center

- ★ Ebrahim Haroon, M.D.
Emory University School of Medicine

Michael Henry, M.D.
Massachusetts General Hospital

Susan Kornstein, M.D.
Virginia Commonwealth University

Maria Lisotto, M.D.
Massachusetts General Hospital/McLean Hospital

- ★ Timothy Mariano, M.D., Ph.D.
Harvard Medical School

Sanjay Mathew, M.D.
Baylor College of Medicine

Barbara Milrod, M.D.
Weill Cornell University

- ★ Francisco Moreno, M.D.
University of Arizona

Mark Pollack, M.D.
Rush University Medical Center

- ★ Rajiv Radhakrishnan, M.D.
Yale School of Medicine

- ★ Erika Saunders, M.D.
Pennsylvania State College of Medicine

Shamecca Scott, Psy.D.
MindSet, LLC

- ★ Jair Soares, M.D.
University of Texas School of Medicine at Houston

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

Program Committee (continued)

Oleg Tcheremissine, M.D.
Carolinas HealthCare System

Antonio Teixeira, M.D.
University of Texas Health Science Center at Houston

- ★ Susannah Tye, Ph.D.
The University of Queensland
- ★ Carlos A. Zarate, M.D.
National Institute of Mental Health
- ★ Jianping Zhang, M.D., Ph.D.
The Zucker Hillside Hospital
- ★ Mark Zimmerman, M.D.*
Brown University

New Investigator Award Program Committee

- ★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital
- ★ Lori Davis, M.D.
Tuscaloosa VA Medical Center
- ★ Michael Davis, M.D., Ph.D.
US Food and Drug Administration
- ★ Tiffany Farchione, M.D.
US Food and Drug Administration
- Bruce Kinon, M.D.
Lundbeck
- Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse
- Lynn Morin, M.A.
National Institute on Alcohol Abuse and Alcoholism
- ★ Katharine Phillips, M.D.
Weill Cornell Medical College/NewYork-Presbyterian Hospital
- Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center
- ★ Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

ASCP Officers and Board

Michael E. Thase, M.D. – ASCP President
University of Pennsylvania

Mark Rapaport, M.D. – ASCP Past-President
Emory University School of Medicine

John Newcomer, M.D. – ASCP Treasurer
Charles E. Schmidt College of Medicine, Florida Atlantic University

- ★ Madhukar Trivedi, M.D. – ASCP President-elect
UT Southwestern Medical Center

Leslie Citrome, M.D., M.P.H. – ASCP Treasurer-elect
New York Medical College

Joseph Calabrese, M.D.
University Hospitals Cleveland Medical Center

- ★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

- ★ Kristina Deligiannidis, M.D.
Zucker Hillside Hospital; Feinstein Institute for Medical Research; Hofstra
Northwell School of Medicine

Marlene Freeman, M.D.*
Massachusetts General Hospital

- ★ Joseph Goldberg, M.D.*
Icahn School of Medicine at Mount Sinai

John Kane, M.D.
The Zucker Hillside Hospital

Stephen Marder, M.D.
Semel Institute at UCLA

- ★ Katharine Phillips, M.D.
Weill Cornell Medical College/NewYork-Presbyterian Hospital

Trisha Suppes, M.D., Ph.D.*
Stanford University

Sidney Zisook, M.D.
University of California, San Diego

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

Meeting Services

Registration Desk* Hours:

Monday	10:00 a.m. – 5:00 p.m.
Tuesday	7:30 a.m. – 6:00 p.m.
Wednesday	7:30 a.m. – 7:00 p.m.
Thursday	7:30 a.m. – 6:00 p.m.
Friday	7:30 a.m. – 12:00 p.m.

*The registration/meeting information desk is located in the Rotunda East on the Second Level.

The ASCP Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Sundial meeting room, on the Third Level.

Monday	12:00 p.m. – 5:00 p.m.
Tuesday - Thursday	7:30 a.m. – 6:30 p.m.
Friday	7:30 a.m. – 10:30 a.m.

ASCP Wi-Fi

Network: ascp2018

Access PIN: ascp2018

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Discounts – All ASCP Annual Meeting attendees who booked their room at the Loews Miami Beach through the ASCP meeting website will have the following resort amenities complimentary:

- Access to standard high-speed internet in the guest rooms
- Fitness Center admittance
- Access to newspapers with Loews mobile app

ASCP Membership - If you would like to join ASCP, you can log onto our website at <https://www.ascpp.org/> and register online. Membership applications are available at the ASCP membership booth, located next to the meeting registration desk in the Rotunda East on the Second Level. You may also contact the ASCP office at 615-649-3085 to request one.

ASCP Fellow Membership

If you have been a member of ASCP for 10+ consecutive years and attended 5 or more meetings, or been a member of ASCP for 20+ consecutive years, you may be eligible for fellowship membership. Contact ASCP's Executive Office, info@ascpp.org, for more information or to confirm your status.

Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. **Self-assessment maintenance of certification credits** are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the meeting at www.ASCPMeeting.org. **Surveys for continuing education credit must be submitted no later than Monday, July 02, 2018.** There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE ANNUAL MEETING AND HAS APPROVED THIS PROGRAM AS PART OF A COMPREHENSIVE SELF-ASSESSMENT PROGRAM, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF MAINTENANCE OF CERTIFICATION.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians and Pharmacists



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Society of Clinical Psychopharmacology (ASCP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American

Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of *20.75 AMA PRA Category 1 Credits™* for physicians and 20.75 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists

This course is co-sponsored by Amedco and ASCP. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. Maximum of 20.75 hours. Partial credit will not be awarded.

All participants who request continuing education credits by Monday, July 02, 2018, should expect to receive their statement of credits via email in July.

The Meeting Evaluation Survey will be available at www.ASCPMeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. There is a \$40.00 administrative fee for CME/CE applications. Your candid input on the 2018 meeting is appreciated as we strive to improve the meeting each year.

ASCP | Meeting Announcements

ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

ACADIA Pharmaceuticals Inc.
Alkermes, Inc.
Avanir Pharmaceuticals
Neurocrine Biosciences, Inc.
Otsuka and Lundbeck
Sunovion Pharmaceuticals, Inc.
Supernus Pharmaceuticals
Vanda Pharmaceuticals Inc.

2019 ASCP Annual Meeting – Save the Date



Fairmont
SCOTTSDALE PRINCESS



The 2019 ASCP Annual Meeting will take place May 27 – 31, 2019 at the Fairmont Scottsdale Princess in Scottsdale, Arizona. Details regarding abstract submission for the 2019 Annual Meeting will be released in September 2018.

AT-A-GLANCE

Monday, May 28, 2018

- 8:00 a.m. - 4:55 p.m. **New Investigator Award (NIA) Workshop
(Invitation Only)**
Cowrie 2
- 10:00 a.m. - 5:00 p.m. **Registration**
Rotunda East
- 12:00 p.m. - 5:00 p.m. **Speaker Ready Room**
Sundial

FULL SCHEDULE**Monday, May 28, 2018**

**8:00 a.m. - 4:55 p.m. New Investigator Award (NIA) Workshop
(Invitation Only)
Cowrie 2**

Co-Chairs: Mark Rapaport, Emory University School of Medicine
Christopher Sarampote, National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions and orals during the Individual Research Reports on Tuesday, May 29, 2018. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an awards ceremony on Tuesday evening, May 29, 2018. This year marks the 26th year of the New Investigator program with 20 New Investigator awardees that are indicated with a ribbon in the poster section of this program; they will also be notated with a ribbon icon in the program book.

Faculty

Michael Davis
US Food and Drug Administration
Tiffany R. Farchione
US Food and Drug Administration
Bruce Kinon
Lundbeck
Iván Montoya
National Institute on Drug Abuse

Lynn Morin
National Institute on Alcohol Abuse
and Alcoholism
Holly Swartz
University of Pittsburgh
Nina Schooler
SUNY Downstate Medical Center

10:00 a.m. - 5:00 p.m. **Registration**
Rotunda East

12:00 p.m. - 5:00 p.m. **Speaker Ready Room**
Sundial

AT-A-GLANCE

Tuesday, May 29, 2018

- 7:30 a.m. - 6:00 p.m. **Registration**
Rotunda East
- 7:30 a.m. - 6:30 p.m. **Speaker Ready Room**
Sundial
- 7:30 a.m. - 8:30 a.m. **NIA Breakfast Roundtable (Invitation Only)**
Neptune
- 7:30 a.m. - 9:00 a.m. **Morning Break**
Americana Foyer
- 8:30 a.m. - 9:00 a.m. **Conference Opening**
Salon 3
- 9:00 a.m. - 10:30 a.m. **Panel Sessions**

ACTIVE Update: Reduction in World Health Organization (WHO) Drinking Risks Level as a Primary Endpoint for Alcohol Treatment Trials	Herbal and Nutraceutical Agents for Schizophrenia: Recent Clinical Trials*	Identifying Moderators of Antidepressant Treatment and Strategies to Reduce Placebo Response: Findings From the EMBARC Study*	It's Not Just Autism: ASD and Associated Psychopathology and Cognitive Dysfunction*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

- 10:30 a.m. - 10:45 a.m. **Break**
Americana Foyer

10:45 a.m. - 12:15 p.m. **Panel Sessions**

The Opioid Epidemic: Crisis and Solutions*	Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment	Early-Phase Trials of Novel Interventions for Treatment-Resistant Depression	Enhancing Medication Adherence in Clinical Trials: Challenges and Opportunities
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

12:15 p.m. - 1:45 p.m. **Early Career Luncheon (RSVP Only)+**
Cowrie 1-2

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipelines+**
Salon 3

4:00 p.m. - 4:15 p.m. **Break**
Americana Foyer

4:15 p.m. - 5:30 p.m. **Individual Research Reports**

Biomarkers and Neural Correlates	Individualizing Treatment and Assessment*	Interventions for Bipolar and Psychotic Disorders*	Studies in MDD: New Approaches and Treatments*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

5:30 p.m. - 6:15 p.m. **ASCP JCP Liaison Task Force Meeting (Invitation Only)**
Boardroom

6:15 p.m. - 7:45 p.m. **New Investigator Awards Ceremony (Invitation Only)**
Cowrie 1-2

**Of Special Interest To Clinicians +No CME Credits Offered*

FULL SCHEDULE

Tuesday, May 29, 2018

- 7:30 a.m. - 6:00 p.m. **Registration**
Rotunda East
- 7:30 a.m. - 6:30 p.m. **Speaker Ready Room**
Sundial
- 7:30 a.m. - 8:30 a.m. **NIA Breakfast Roundtable (Invitation Only)**
Neptune
- 7:30 a.m. - 9:00 a.m. **Morning Break**
Americana Foyer
- 8:30 a.m. - 9:00 a.m. **Conference Opening**
Salon 3

Panel Sessions

- 9:00 a.m. - 10:30 a.m. **ACTIVE Update: Reduction in World Health Organization (WHO) Drinking Risks Level as a Primary Endpoint for Alcohol Treatment Trials**
Poinciana 1-2

Chair: Stephanie O'Malley, Yale University School of Medicine

Discussant: Bernard Silverman, Alkermes, Inc.

- 9:00 a.m. - 9:10 a.m. **Introduction**
- 9:10 a.m. - 9:30 a.m. **Change in WHO Risk Drinking Levels and Clinical Outcomes: Findings From the US General Population**
Deborah Hasin, Columbia University
- 9:30 a.m. - 9:50 a.m. **The Relationship of World Health Organization Drinking Risk Levels to How Patients "Feel and Function" in an Alcohol Clinical Trial**
Katie Witkeiwitz, University of New Mexico

**Of Special Interest To Clinicians +No CME Credits Offered*

9:00 a.m. - 10:30 a.m. (continued) **ACTIVE Update: Reduction in World Health Organization (WHO) Drinking Risks Level as a Primary Endpoint for Alcohol Treatment Trials**
Poinciana 1-2

9:50 a.m. - 10:10 a.m. **Measuring Response to Alcohol Pharmacotherapy: Efficacy Endpoints Based on Reductions in the World Health Organization (WHO) Risk Levels of Alcohol Consumption**
Daniel Falk, NIAAA/NIH

10:10 a.m. – 10:30 a.m. **Discussion+**

9:00 a.m. - 10:30 a.m. **Herbal and Nutraceutical Agents for Schizophrenia: Recent Clinical Trials***
Poinciana 3-4

Chair: Stephen Marder, Semel Institute at UCLA

Discussant: Roy Chengappa, University of Pittsburgh Medical Center

9:00 a.m. - 9:10 a.m. **Introduction**

9:10 a.m. - 9:30 a.m. **A Randomized Double-Blind Placebo-Controlled Study of Curcumin Nanoparticles on Cognition and Brain Derived Neurotrophic Factor in Schizophrenia**
Jonathan Wynn, VA Greater Los Angeles Healthcare System/UCLA

9:30 a.m. - 9:50 a.m. **Effects of 12-Month, Double-Blind N-Acetyl Cysteine on Symptoms, Cognition and Brain Morphology in Early Phase Schizophrenia**
Alan Breier, Indiana University School of Medicine

9:50 a.m. - 10:10 a.m. **Withania Somnifera as an Adjuvant Treatment of Exacerbated Schizophrenia: A Novel Approach to Negative Symptoms?**
Jessica Gannon, University of Pittsburgh School of Medicine

10:10 a.m. - 10:30 a.m. **Ashwaganda May Recover Brain Function in Long-Term Schizophrenia**
Dean Salisbury, University of Pittsburgh School of Medicine

**Of Special Interest To Clinicians +No CME Credits Offered*

**9:00 a.m. - 10:30 a.m. Identifying Moderators of Antidepressant Treatment and Strategies to Reduce Placebo Response: Findings From the EMBARC Study*
Salon 1**

Chair: Madhukar Trivedi, UT Southwestern Medical Center

Co-Chair: Manish Jha, UT Southwestern

Discussant: Maurizio Fava, Massachusetts General Hospital

9:00 a.m. - 9:10 a.m. **Introduction**

9:10 a.m. - 9:30 a.m. **Systematic Exploration of Clinical, Sociodemographic, Electrophysiologic and Neuroimaging Markers to Predict Placebo Response: Findings From EMBARC Study**
Manish Jha, UT Southwestern

9:30 a.m. - 9:50 a.m. **Personalized Prediction of Antidepressant Versus Placebo Response: Evidence From the EMBARC Study**
Christian Webb, Harvard Medical School McLean Hospital

9:50 a.m. - 10:10 a.m. **Examination of Reward-Related Ventral Striatal Activity in Relation to Treatment Response in Major Depressive Disorder**
Tsafir Greenberg, University of Pittsburgh School of Medicine

10:10 a.m. - 10:30 a.m. **Identifying Predictors of Antidepressant Treatment Response in Major Depressive Disorder Using Resting-State Brain Imaging**
Crystal Cooper, The University of Texas Southwestern Medical Center

9:00 a.m. - 10:30 a.m. **It's Not Just Autism: ASD and Associated Psychopathology and Cognitive Dysfunction***
Salon 2

Chair: Gagan Joshi, Massachusetts General Hospital

Discussant: Barbara Coffey, University of Miami Miller School of Medicine

9:00 a.m. - 9:10 a.m. **Introduction**

9:10 a.m. - 9:30 a.m. **Neuropsychological Correlates of Autism Spectrum Disorders: A Controlled Study of Adults with High Functioning ASD**
Ronna Fried, MGH/Harvard Medical School

9:30 a.m. - 9:50 a.m. **Autistic Traits in Children With and Without ADHD**
Joseph Biederman, Massachusetts General Hospital

9:50 a.m. - 10:10 a.m. **High Risk for Severe Emotional Dysregulation in Psychiatrically Referred Youth With Autism Spectrum Disorder: A Controlled Study**
Janet Wozniak, Harvard Medical School, Massachusetts General Hospital

10:10 a.m. - 10:30 a.m. **MR Spectroscopic Glutamate Activity in High-Functioning Autism Spectrum Disorder Adolescents With and Without Emotional Dysregulation**
Gagan Joshi, Massachusetts General Hospital

10:30 a.m. - 10:45 a.m. **Break**
Americana Foyer

Panel Sessions

10:45 a.m. - 12:15 p.m. The Opioid Epidemic: Crisis and Solutions*
Poinciana 1-2

Chair: Phil Skolnick, Opiant Pharmaceuticals, Inc.

Co-Chair: Sandra Comer, Columbia University & New York State Psychiatric Institute

Discussant: Edward Nunes, NYSPI - Columbia University

10:45 a.m. - 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **Overdose: The Leading Edge of the Opioid Epidemic**
Roger Crystal, Opiant Pharmaceuticals, Inc.

11:15 a.m. - 11:35 a.m. **Emerging Medications for Opioid Use Disorder**
Genie Bailey, Brown University

11:35 a.m. - 11:55 a.m. **Development of a Heroin Vaccine That Induces Antibodies That Also Bind to Abused Prescription Opioids**
Gary Matyas, Walter Reed Army Institute of Research

11:55 a.m. - 12:15 p.m. **Using Mu Opioid Receptor Biased Agonism to Refine Opioid Analgesics**
Laura Bohn, The Scripps Research Institute

10:45 a.m. - 12:15 p.m. Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment
Poinciana 3-4

Chair: Beatrice Setnik, Syneos Health

Discussant: Beatrice Setnik, Syneos Health

10:45 a.m. - 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **A GPS for THC: Looking for a Science-Based Regulatory Framework for Cannabinoid Medicines When We Can't Decide Which Way Is Up**
Michael Hufford, Pinney Associates

**Of Special Interest To Clinicians +No CME Credits Offered*

10:45 a.m. - 12:15 p.m. (continued) **Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment**
Poinciana 3-4

11:15 a.m. - 11:35 a.m. **Cannabinoids: A Driving Force - Evaluating Methodological and Clinical Challenges to Testing Abuse Potential and Driving Impairment**
Talar Hopyan, Syneos Health

11:35 a.m. - 11:55 a.m. **Selecting Subjective Behavioral and Objective Cognitive Measures for Clinical Trials of Cannabis and Driving Impairment**
Denise Milovan, INC Research

11:55 a.m. - 12:15 p.m. **Discussion**

10:45 a.m. - 12:15 p.m. **Early-Phase Trials of Novel Interventions for Treatment-Resistant Depression**
Salon 1

Chair: Brian Mickey, University of Utah School of Medicine

Discussant: Mark Rapaport, Emory University School of Medicine

10:45 a.m. - 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **Psilocybin for Major Depressive Disorder**
Robin Carhart-Harris, Imperial College London

11:15 a.m. - 11:35 a.m. **Clinical Trials of 5-Hydroxytryptophan and Creatine Monohydrate for SSRI or SNRI Augmentation in Treatment-Resistant Depression in Women**
Brent Kious, University of Utah

11:35 a.m. - 11:55 a.m. **Enhancing Neuroplasticity and Cellular Resilience as Novel Pharmacological Approaches to Treatment-Resistant Depression**
James Murrough, Icahn School of Medicine at Mount Sinai

11:55 a.m. - 12:15 p.m. **Antidepressant Effects of Deep Propofol Anesthesia**
Brian Mickey, University of Utah School of Medicine

**Of Special Interest To Clinicians +No CME Credits Offered*

10:45 a.m. - 12:15 p.m. Enhancing Medication Adherence in Clinical Trials: Challenges and Opportunities
Salon 2

Chair: Mary Rooney, National Institute of Mental Health

Discussant: Matthew Rudorfer, National Institutes of Health/NIMH

10:45 a.m. - 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **Adherence in Schizophrenia: Lessons Learned From RAISE-ETP, the Use of Long Acting Injectables and Other Strategies**

John Kane, The Zucker Hillside Hospital

11:15 a.m. - 11:35 a.m. **Treatment Adherence in Bipolar Disorder**

Martha Sajatovic, University Hospitals Case Medical Center

11:35 a.m. - 11:55 a.m. **Enhancing Medication Adherence in Clinical Trials: Challenges and Opportunities**

Adam Hanina, AiCure

11:55 a.m. - 12:15 p.m. **Discussion**

12:15 p.m. - 1:45 p.m. Early Career Luncheon (RSVP Only)+
Cowrie 1-2

The Early Career Luncheon is an engaging opportunity to meet colleagues and learn about work life balance as well as participate in a 30-45 minute roundtable discussion. The following presenters will be in attendance

- Michael Davis, FDA, Chair
- Ross Baker, Otsuka
- Mirjana Domakonda, Hartford Hospital / Institute of Living
- Dawn Ionescu, Janssen Research and Development
- Kari Nations, Syneos Health
- Katharine Phillips, Weill Cornell Medical College

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipeline Presentations+
Salon 3**

Chair: Carlos Zarate, National Institute on Mental Health

Co-Chair: Leslie Citrome, New York Medical College

- 2:00 p.m. - 2:10 p.m. **Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression**
Vanina Popova, Neuroscience TA, Janssen R & D, LLC, Janssen Pharmaceutical Companies of JNJ
- 2:10 p.m. - 2:20 p.m. **A Proof-Of-Mechanism Study of the PDE10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms Probing Reward Functions With Imaging and Behavioral Approaches**
Daniel Umbricht, F. Hoffmann-La Roche Ltd
- 2:20 p.m. - 2:30 p.m. **Moving Beyond Efficacy and Safety to Real-World Usability in the Digital Medicine Era**
Timothy Peters-Strickland, Otsuka Pharmaceutical Development and Commercialization
- 2:30 p.m. - 2:40 p.m. **NIMH Fast-Mas Phase IIa Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activation During the Monetary Incentive Delay Test in Anhedonic Patients With Mood and Anxiety Spectrum Disorders**
Andrew Krystal, UCSF
- 2:40 p.m. - 2:50 p.m. **Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients With Major Depressive Disorder**
James Murrough, Icahn School of Medicine at Mount Sinai
- 2:50 p.m. - 3:00 p.m. **MDMA-Assisted Psychotherapy for Treatment of Chronic Posttraumatic Stress Disorder (PTSD): Findings From Phase 2 Clinical Research Trials**
Allison Feduccia, MAPS Public Benefit Corporation

**Of Special Interest To Clinicians +No CME Credits Offered*

2:00 p.m. - 4:00 p.m. (continued)	Pharmaceutical Pipeline Presentations+ Salon 3
3:00 p.m. - 3:10 p.m.	The Relationship Between Cognition and Depression Improvement Among MDD Patients by NSI-189, a Neurogenic, Pro-cognitive, Antidepressant Compound Karl Johe, Neuralstem, Inc.
3:10 p.m. - 3:20 p.m.	Efficacy and Safety of MIN-101: A New Compound for the Treatment of Negative Symptoms in Schizophrenia a 12-Week Randomized, Double Blind, Placebo-Controlled Trial Michael Davidson, Tel-Aviv University Sackler Faculty and Minerva Neurosciences
3:20 p.m. - 3:30 p.m.	Lofexidine for Treatment of Opioid Withdrawal Symptoms: A Double-Blind, Placebo-Controlled, Multicenter Trial in Opioid-Dependent Subjects Danesh Alam, Northwestern Medicine Central Dupage
3:30 p.m. - 3:40 p.m.	The GABA-A Receptor Positive Allosteric Modulators Brexanolone IV and SAGE-217 in the Treatment of Mood Disorders: Results From Recent Placebo-Controlled Studies Stephen Kanes, Sage Therapeutics
3:40 p.m. - 3:50 p.m.	A Randomized Withdrawal, Double-Blind, Multicenter Study of Esketamine Nasal Spray Plus an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression Ella Daly, Johnson & Johnson PRD
4:00 p.m. - 4:15 p.m.	Break <i>Americana Foyer</i>

Individual Research Reports

4:15 p.m. - 5:30 p.m. Biomarkers and Neural Correlates
Poinciana 1-2

Chair: Rajiv Radhakrishnan, Yale School of Medicine

4:15 p.m. - 4:20 p.m. **Introduction**

4:20 p.m. - 4:35 p.m. **Epigenetic Mechanisms in Substance Use Disorder Quantified by Non-Invasive PET Imaging**

Changning Wang, Harvard Medical School/
Massachusetts General Hospital



4:35 p.m. - 4:50 p.m. **Epigenetic Disinhibition of FKBP5 by Aging and Stress Contributes to Inflammation and Cardiovascular Risk**

Anthony Zannas, Max-Planck Institute of Psychiatry

4:50 p.m. - 5:05 p.m. **Neural Correlates of Eating Behavior**

Lawrence Maayan, Nathan Kline Institute



5:05 p.m. - 5:20 p.m. **Association of Depressive and Suicidal Symptom Improvement After Ketamine Administration With Default Mode Connectivity Changes**

Jennifer Evans, National Institute of Mental Health

5:20 p.m. - 5:30 p.m. **Discussion**

4:15 p.m. - 5:30 p.m. Individualizing Treatment and Assessment*
Poinciana 3-4

Chair: Cristina Cusin, Massachusetts General Hospital

4:15 p.m. - 4:20 p.m. **Introduction**



4:20 p.m. - 4:35 p.m. **A Computational Approach to Psychosis Detection and Personalized Treatment**

Albert Powers, CT Mental Health Center, Yale University



= **New Investigator Awardee**

**Of Special Interest To Clinicians +No CME Credits Offered*

4:15 p.m. - 5:30 p.m. (continued)	Individualizing Treatment and Assessment* <i>Poinciana 3-4</i>
4:35 p.m. - 4:50 p.m.	Prediction of Clinical Depression Using Smartphone Sensory Data Jayesh Kamath, University of Connecticut Health Center
4:50 p.m. - 5:05 p.m.	Assessment of IADL Functioning in Individuals With Subjective Cognitive Complaints Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Alexandra Atkins, NeuroCog Trials
5:05 p.m. - 5:20 p.m.	Randomized Controlled Trial Testing the Effectiveness of an “Adaptive SMART” Stepped-Care Multi-Modal Treatment for Adults With Obesity and Binge Eating Disorder Carlos Grilo, Yale University School of Medicine
5:20 p.m. - 5:30 p.m.	Discussion
4:15 p.m. - 5:30 p.m.	Interventions for Bipolar and Psychotic Disorders* <i>Salon 1</i>

Chair: Pratik Bahekar, SUNY Downstate Medical Center

4:15 p.m. - 4:20 p.m.	Introduction
4:20 p.m. - 4:35 p.m.	A Double-Blind Randomized Placebo-Controlled Study of Aspirin and N-Acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder: Preliminary Findings Isabelle Bauer, The University of Texas Health Science Center at Houston
4:35 p.m. - 4:50 p.m.	Cariprazine Treatment of Bipolar I Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study+ Willie Earley, Allergan

**Of Special Interest To Clinicians +No CME Credits Offered*

4:15 p.m. - 5:30 p.m.
(continued)

Interventions for Bipolar and Psychotic Disorders*
Salon 1

4:50 p.m. - 5:05 p.m.

Comparison of the Efficacy and Safety of Atypical Antipsychotics for the Treatment of Schizophrenia Between Adolescents and Adults
Shamir Kalaria, University of Maryland School of Pharmacy

5:05 p.m. - 5:20 p.m.

Pimavanserin: Potential Treatment for Psychotic Symptoms Across Neurodegenerative Diseases
Clive Ballard, ACADIA Pharmaceuticals, Inc

5:20 p.m. - 5:30 p.m.

Discussion

4:15 p.m. - 5:30 p.m.

Studies in MDD: New Approaches and Treatments
Salon 2

Chair: Timothy Mariano, Harvard Medical School

4:15 p.m. - 4:20 p.m.

Introduction



4:20 p.m. - 4:35 p.m.

Identifying Characteristics of Placebo Responders in Major Depression From the EMBARC Study
Charles South, UTSW Medical Center Dallas

4:35 p.m. - 4:50 p.m.

Have Treatment Studies of Depression Become Even Less Generalizable? Applying the Inclusion and Exclusion Criteria in Placebo Controlled Antidepressant Efficacy Trials Published over 20 Years to a Clinical Sample
Mark Zimmerman, Brown University

4:50 p.m. - 5:05 p.m.

Age, Treatment and Baseline Severity as Factors in Suicidal Behavior in Randomized Placebo-Controlled Trials in Major Depressive Disorder
Marc Stone, FDA/CDER/DPP



= New Investigator Awardee

*Of Special Interest To Clinicians +No CME Credits Offered

4:15 p.m. - 5:30 p.m. (continued)	Studies in MDD: New Approaches and Treatments <i>Salon 2</i>
5:05 p.m. - 5:20 p.m.	SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator Being Developed for Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase II Placebo-Controlled Trial+ Stephen Kanés, Sage Therapeutics
5:30 p.m. - 6:15 p.m.	ASCP JCP Liaison Task Force Meeting (Invitation Only) <i>Boardroom</i>
6:15 p.m. - 7:45 p.m.	New Investigator Awards Ceremony (Invitation Only) <i>Cowrie 1-2</i>

AT-A-GLANCE

Wednesday, May 30, 2018

- 6:30 a.m. - 8:00 a.m. **19th Annual ASCP Fun Run/Walk – Open to ALL Attendees! (No prior sign up necessary)**
St. Moritz Lawn
- 7:00 a.m. - 8:00 a.m. **ISCTM and ASCP Collaboration Meeting (Invitation Only)**
Crown Conch
- 7:30 a.m. - 7:00 p.m. **Registration**
Rotunda East
- 7:30 a.m. - 6:30 p.m. **Speaker Ready Room**
Sundial
- 7:30 a.m. - 8:30 a.m. **NIA Breakfast Roundtable (Invitation Only)**
Neptune
- 7:30 a.m. - 9:00 a.m. **Morning Break**
Americana Foyer
- 8:30 a.m. - 10:00 a.m. **Regulatory Plenary: Autism Spectrum Disorder**
Salon 3
- 10:00 a.m. - 10:15 a.m. **Break**
Americana Foyer
- 10:15 a.m. - 11:15 a.m. **ASCP Awards Ceremony and ASCP Lifetime Awardee Talk – Phil Skolnick, Ph.D.: Reflections on the Development of Glutamate-Based Antidepressants**
Salon 3
- 11:15 a.m. - 1:00 p.m. **Early Career Networking Tables (Open to all Attendees)**
Americana Foyer
- 11:15 a.m. - 1:00 p.m. **Poster Session I with Lunch+**
Salon 4

**Of Special Interest To Clinicians +No CME Credits Offered*

11:15 a.m. - 11:45 a.m. **ASCP Women's Initiative Meeting (Invitation Only)**
Cowrie 2

1:00 p.m. - 2:30 p.m. **Panel Sessions**

New Perspectives on Treatment Resistant Schizophrenia (TRS)	Long-Term Medication for Axis I Disorders: Lifetime Treatment or Not?*	Treatment of Resistant Depression With Ketamine: Similarities and Differences With ECT*	Geriatric Psychopharmacology Update: Findings, Challenges, and New Opportunities*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

2:30 p.m. - 2:45 p.m. **Break**
Americana Foyer

2:45 p.m. - 4:45 p.m. **Workshops**

An AFSP/ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time	Early Career Workshop: How to Get Published	30 Years of the PANSS in Schizophrenia: Where are We Now and Where are We Headed?	FDA's Initiatives to Optimize Pediatric Clinical Development for Psychiatric Products
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

5:00 p.m. - 6:00 p.m. **ASCP Business Meeting & Reception (ASCP Members Only)**
Poinciana 3-4

6:00 p.m. - 7:00 p.m. **ASCP Reception**
Americana Lawn

7:00 p.m. - 10:00 p.m. **ASCP Board of Directors Meeting (Invitation Only)**
Boardroom

**Of Special Interest To Clinicians +No CME Credits Offered*

FULL SCHEDULE

Wednesday, May 30, 2018

- 6:30 a.m. - 8:00 a.m.** **19th Annual ASCP Fun Run/Walk – Open to ALL Attendees!**
All participants receive a FREE ASCP T-shirt!
St. Moritz Lawn
- 7:00 a.m. - 8:00 a.m.** **ISCTM and ASCP Collaboration Meeting (Invitation Only)**
Crown Conch
- 7:30 a.m. - 7:00 p.m.** **Registration**
Rotunda East
- 7:30 a.m. - 6:30 p.m.** **Speaker Ready Room**
Sundial
- 7:30 a.m. - 8:30 a.m.** **NIA Breakfast Roundtable (Invitation Only)**
Neptune
- 7:30 a.m. - 9:00 a.m.** **Morning Break**
Americana Foyer
- 8:30 a.m. - 10:00 a.m.** **Regulatory Plenary: Autism Spectrum Disorder**
Salon 3

Chair: John Newcomer, Charles E. Schmidt College of Medicine, Florida Atlantic University

Presenters: Tiffany Farchione, US Food and Drug Administration
Valentina Mantua, AIFA

This year's Regulatory Plenary will focus on FDA and EMA initiatives related to Autism Spectrum Disorder (ASD) and other neurodevelopmental disorders. FDA will discuss last year's Patient Focused Drug Development meeting on ASD and the recently published *Voice of the Patient* report. FDA will also describe collaborative efforts between FDA and EMA to align regulatory advice related to ASD and other neurodevelopmental disorders. EMA will provide an update on EU-AIMS (the Innovative Medicines Initiative project exploring potential biomarkers in ASD). EMA will also discuss the strengths and limitations of their Guideline on the clinical development of medicinal products for the treatment of Autism Spectrum Disorder.

**Of Special Interest To Clinicians +No CME Credits Offered*

10:00 a.m. - 10:15 a.m. **Break**
Americana Foyer

10:15 a.m. - 11:15 a.m. **ASCP Awards Ceremony and ASCP Lifetime Awardee Talk - Phil Skolnick, Ph.D.: Reflections on the Development of Glutamate-Based Antidepressants**
Salon 3

Awards Presented to:

2018 Best Paper in *The Journal of Clinical Psychiatry* Award: Philip

Gerretsen, Centre for Addiction and Mental Health

Nominated For: *Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism*

2017 Early Career Research Award: Yash Joshi, University of California, San Diego. See his award-winning research at Poster 43 on Thursday, May 31, 2018 from 12:30 p.m. – 2:00 p.m.

Lifetime Awardee: Phil Skolnick, Opiant Pharmaceuticals

Three decades after the first hypothesis driven study demonstrating antidepressant-like effects of N-methyl-D-aspartate (NMDA) antagonists, esketamine (the S-enantiomer of ketamine, an ion channel blocker) and rapastinel (an NMDA receptor linked glycine site partial agonist) are in late stage development for treatment resistant depression. The dramatic antidepressant effects produced by intravenous infusion of subanesthetic doses of ketamine, taken together with an emerging understanding of glutamatergic signaling, suggests the glutamatergic synapse contains multiple targets for antidepressant development. Despite some modest efficacy signals emerging from large, well-controlled clinical studies with other glutamate-based drugs (ranging from lanicemine, an NMDA ion channel blocker, to basmiglurant, a negative allosteric modulator at mGluR5 receptors), the rapid and robust effects of ketamine in treatment resistant depression could be viewed as an apparent anomaly rather than a characteristic of this drug class. In this presentation, I will review preclinical and clinical data with an eye toward features which potentially distinguish ketamine from other glutamate-based agents and reflect on the viability of the glutamatergic synapse as a target for future drug development.

- 11:15 a.m. - 1:00 p.m.** **Early Career Networking Tables**
(Open to all Attendees)
Americana Foyer
- 11:15 a.m. - 1:00 p.m.** **Poster Session I with Lunch+**
Salon 4
See pages 73-83 for a complete listing of posters.
- 11:15 a.m. - 11:45 a.m.** **ASCP Women's Initiative Meeting**
(Invitation Only)
Cowrie 2

Panel Sessions

- 1:00 p.m. - 2:30 p.m.** **New Perspectives on Treatment Resistant Schizophrenia (TRS)**
Poinciana 1-2

Chair: John Kane, The Zucker Hillside Hospital
Discussant: Stephen Marder, Semel Institute at UCLA

- 1:00 p.m. - 1:10 p.m.** **Introduction**
- 1:10 p.m. - 1:30 p.m.** **The Group of Treatment Resistant Schizophrenias?+**
Bruce Kinon, Lundbeck
- 1:30 p.m. - 1:50 p.m.** **Is There Continuity Between Breakthrough on Antipsychotic Maintenance Medication (BAMM) and Treatment Resistant Schizophrenia (TRS)? New Opportunities for Identification and Intervention**
Jose Rubio, Hofstra NS-LIJ School of Medicine
- 1:50 p.m. - 2:10 p.m.** **Clinical Trials in TRS: The Good, the Bad and the Ugly**
John Kane, The Zucker Hillside Hospital
- 2:10 p.m. - 2:30 p.m.** **Discussion**

1:00 p.m. - 2:30 p.m. **Long-Term Medication for Axis I Disorders:
Lifetime Treatment or Not?***
Poinciana 3-4

Chair: Ira Glick, Stanford University School of Medicine

Discussant: William Potter, National Institute of Mental Health

1:00 p.m. - 1:10 p.m. **Introduction**

1:10 p.m. - 1:30 p.m. **Long Term Prophylaxis After a First Manic
Episode**

Robert Post, Bipolar Collaborative Network

1:30 p.m. - 1:50 p.m. **Maintenance Treatment for Depression: To
Discontinue or Not**

Madhukar Trivedi, UT Southwestern Medical Center

1:50 p.m. - 2:10 p.m. **Should Antipsychotic Medications for
Schizophrenia be Given for a Lifetime?**

Ira Glick, Stanford University School of Medicine

2:10 p.m. - 2:30 p.m. **Discussion**

1:00 p.m. - 2:30 p.m. **Treatment of Resistant Depression With
Ketamine: Similarities and Differences With ECT***
Salon 1

Chair: Amit Anand, Cleveland Clinic Lerner School of Medicine of Case
Western University

Discussant: Amit Anand, Cleveland Clinic Lerner School of Medicine of Case
Western University

1:00 p.m. - 1:10 p.m. **Introduction**

1:10 p.m. - 1:30 p.m. **Ketamine Dose Frequency and Short-Term
Outcomes in Treatment-Resistant Depression**

Sanjay Mathew, Baylor College of Medicine

1:30 p.m. - 1:50 p.m. **Comparing and Contrasting the Data on the
Rapid Anti-Suicidal Effects of Ketamine and ECT**

Gerard Sanacora, Yale University

1:00 p.m. - 2:30 p.m.
(continued) **Treatment of Resistant Depression With Ketamine: Similarities and Differences With ECT***
Salon 1

1:50 p.m. - 2:10 p.m. **Pharmacological Strategies for Treatment Resistant Depression: Augmentation of Ketamine Therapy and Other Novel Approaches**
James Murrough, Icahn School of Medicine at Mount Sinai

2:10 p.m. - 2:30 p.m. **Temperament as Moderator of Ketamine Response in Treatment Resistant Depression – Experience From a Ketamine Clinical Registry**
Roman Dale, Cleveland Clinic

1:00 p.m. - 2:30 p.m. **Geriatric Psychopharmacology Update: Findings, Challenges, and New Opportunities***
Salon 2

Chair: George Niederehe, National Institute of Mental Health

Discussant: George Niederehe, National Institute of Mental Health

1:00 p.m. - 1:10 p.m. **Introduction**

1:10 p.m. - 1:30 p.m. **Sustaining Remission of Psychotic Depression: The Stop-PD II Study -- Focus on Older Adults**
Ellen Whyte, University of Pittsburgh School of Medicine

1:30 p.m. - 1:50 p.m. **Buprenorphine for Mid- and Late-Life Treatment Resistant Depression: Mechanisms of Action and Clinical Effect**
Jordan Karp, University of Pittsburgh

1:50 p.m. - 2:10 p.m. **Lithium and Divalproex in the Treatment of Older Patients With Bipolar Mania: GERI-BD**
Robert Young, Weill Cornell Medical College

2:10 p.m. - 2:30 p.m. **Discussion**

2:30 p.m. - 2:45 p.m. **Break**
Americana Foyer

**Of Special Interest To Clinicians +No CME Credits Offered*

Workshops

2:45 p.m. - 4:45 p.m. **An AFSP/ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time**
Poinciana 1-2

Co-Chair: Jill Harkavy-Friedman, American Foundation for Suicide Prevention
Co-Chair: Madhukar Trivedi, UT Southwestern Medical Center

Discussants: Luca Pani, European Medicines Agency,
Jean Kim, FDA/CDER/DP

2:45 p.m. - 3:15 p.m. **Introduction**

3:15 p.m. - 3:35 p.m. **Inclusion of Suicidal Individuals in Treatment Trials: Insights From an Ongoing Phase 3 Drug Development Program+**
Carla Canuso, Janssen Research & Development

3:35 p.m. - 3:55 p.m. **Including Suicidal Individuals in Multicenter Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL*, a Novel Formulation of Cyclobenzaprine Hypothesized to Address PTSD Through Improvement in Sleep Quality+**
Gregory Sullivan, Tonix Pharmaceuticals, Inc.

3:55 p.m. - 4:15 p.m. **The NIMH Perspective on Suicide Prevention Research**
Shelli Avenevoli, National Institute of Mental Health/NIH

4:15 p.m. - 4:45 p.m. **Discussion**

2:45 p.m. - 4:45 p.m. **Early Career Workshop: How to Get Published**
Poinciana 3-4

Co-Chair: Ross Baker, Otsuka
Co-Chair: Mirjana Domakonda, Hartford Hospital / Institute of Living

2:45 p.m. - 2:55 p.m. **10 Helpful Tips**
Mirjana Domakonda, Hartford Hospital/Institute of Living

**Of Special Interest To Clinicians +No CME Credits Offered*

2:45 p.m. - 4:45 p.m. (continued) **Early Career Workshop: How to Get Published**
Poinciana 3-4

2:55 p.m. - 3:10 p.m. **Authorship and Industry Papers: How to Get Involved**
Ross Baker, Otsuka

3:10 p.m. - 3:15 p.m. **Discussion**

3:15 p.m. - 3:30 p.m. **What do Journal Editors Look For?**
Leslie Citrome, Editor, *International Journal of Clinical Practice*

3:30 p.m. - 3:45 p.m. **Where to Submit Your Papers**
Marlene Freeman, Editor, *The Journal of Clinical Psychiatry* and Erika Saunders, Editor of the Early Career Psychiatry section of *The Journal of Clinical Psychiatry*

3:45 p.m. - 4:00 p.m. **Discussion**

4:00 p.m. - 4:15 p.m. **The Peer Review Process and Journal Editors Expectations for Peer Reviewers**
Roy Chengappa, Editor, *Bipolar Disorders*

4:15 p.m. - 4:45 p.m. **Discussion**

2:45 p.m. - 4:45 p.m. **30 Years of the PANSS in Schizophrenia: Where are We Now and Where are We Headed?**
Salon 1

Chair: Jean-Pierre Lindenmayer, New York University

Co-Chair: Anzalee Khan, ProPhase LLC

2:45 p.m. - 2:55 p.m. **Introduction**

2:55 p.m. - 3:15 p.m. **Overview of Negative Symptoms and Comparison of Psychometric Properties of the PANSS and Various Alternative Negative Symptom Instruments**
Larry Alphs, Janssen Scientific Affairs, LLC

2:45 p.m. - 4:45 p.m.
(continued)

30 Years of the PANSS in Schizophrenia: Where are We Now and Where are We Headed?
Salon 1

3:15 p.m. - 3:35 p.m.

A 30-Year Voyage: Cross-Cultural Implications in the Use of the PANSS
David Walling, CNS Network, LLC

3:35 p.m. - 3:55 p.m.

Technological innovations in the PANSS: Harnessing the Digital Revolution
Anzalee Khan, ProPhase LLC

3:55 p.m. - 4:15 p.m.

The PANSS: Present State and Future Developments
Jean-Pierre Lindenmayer, New York University

4:15 p.m. - 4:35 p.m.

The Once and Future PANSS
Mark Opler, MedAvante-ProPhase Inc.

4:35 p.m. - 4:45 p.m.

Discussion

2:45 p.m. - 4:45 p.m.

FDA's Initiatives to Optimize Pediatric Clinical Development for Psychiatric Products
Salon 2

Chair: Hao Zhu, U.S. FDA

Co-Chair: Mehul Mehta, Food and Drug Administration

Discussants: Tiffany Farchione, US Food and Drug Administration
Robert Findling, Johns Hopkins University

2:45 p.m. - 2:55 p.m.

Introduction

2:55 p.m. - 3:25 p.m.

Characterization of Placebo Effect in Patients With Bipolar Disorder
Yaning Wang, Center for Drug Evaluation and Research, Food and Drug Administration

3:25 p.m. - 3:55 p.m.

Extension of Efficacy and Safety Findings From Children to Adolescents for the Treatment of Attention Deficit and Hyperactivity Disorder for Some Central Nervous System Stimulant Products
Hao Zhu, U.S. FDA

**Of Special Interest To Clinicians +No CME Credits Offered*

2:45 p.m. - 4:45 p.m. (continued)	FDA's Initiatives to Optimize Pediatric Clinical Development for Psychiatric Products <i>Salon 2</i>
3:55 p.m. - 4:25 p.m.	A Model Based Approach to Establish Disease Similarity in Adults and Adolescents With Schizophrenia Islam Younis, US Food and Drug Administration
4:25 p.m. - 4:45 p.m.	Discussion
5:00 p.m. - 6:00 p.m.	ASCP Business Meeting and Reception (Members Only) <i>Poinciana 3-4</i>
6:00 p.m. - 7:00 p.m.	ASCP Reception <i>Americana Lawn</i>
7:00 p.m. - 10:00 p.m.	ASCP Board of Directors Meeting (Invitation Only) <i>Boardroom</i>

AT-A-GLANCE

Thursday, May 31, 2018

7:00 a.m. - 8:00 a.m.	ASCP Steering Committee Meeting (Invitation Only) Crown Conch
7:15 a.m. - 8:15 a.m.	NIA Breakfast Roundtable (Invitation Only) Neptune
7:30 a.m. - 6:00 p.m.	Registration Rotunda East
7:30 a.m. - 6:30 p.m.	Speaker Ready Room Sundial
7:30 a.m. - 9:00 a.m.	Morning Break Americana Foyer
8:15 a.m. - 9:45 a.m.	Keynote Plenary: Treatment of Psychiatric Illness Across the Lifespan Salon 3
9:45 a.m. - 10:00 a.m.	Break Americana Foyer
10:00 a.m. - 12:30 p.m.	Federal Agency Directors Plenary Salon 3
12:30 p.m. - 1:30 p.m.	ASCP Curriculum Committee Meeting (Invitation Only) Venus
12:30 p.m. - 2:00 p.m.	Early Career Networking Tables (Open to all attendees) Americana Foyer
12:30 p.m. - 2:00 p.m.	Poster Session II with Lunch+ Salon 4
2:00 p.m. - 3:30 p.m.	Clinical Updates in Psychopharmacology* Salon 3

**Of Special Interest To Clinicians +No CME Credits Offered*

3:30 p.m. - 3:45 p.m.

Break

Americana Foyer

3:45 p.m. - 5:45 p.m.

Workshops

Challenges and Implementation of CNS Clinical Trials	Women's Mental Health Across the Lifespan: Knowledge Gained and Evidence Gaps*	Behavioral and Psychological Symptoms of Dementia: Perspectives in Clinical Development From the Division of Psychiatry Products, Food and Drug Administration*	Leadership Skills for Mid-Career Professionals
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

FULL SCHEDULE

Thursday, May 31, 2018

7:00 a.m. - 8:00 a.m.	ASCP Steering Committee Meeting (Invitation Only) <i>Crown Conch</i>
7:15 a.m. - 8:15 a.m.	NIA Breakfast Roundtable (Invitation Only) <i>Neptune</i>
7:30 a.m. - 6:00 p.m.	Registration <i>Rotunda East</i>
7:30 a.m. - 6:30 p.m.	Speaker Ready Room <i>Sundial</i>
7:30 a.m. - 9:00 a.m.	Morning Break <i>Americana Foyer</i>
8:15 a.m. - 9:45 a.m.	Keynote Plenary: Treatment of Psychiatric Illness Across the Lifespan <i>Salon 3</i>

Chair: Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

The 2018 ASCP Plenary Keynote Session will address pivotal topics in psychiatry. Dr. Sandra Comer will present on the abuse of opioids, now a well-recognized public health problem in the U.S. She will address this important issue, with a focus on opioid use disorder (OUD) across the lifespan. While OUD is often recognized in younger and middle-aged people, OUD among older individuals has become increasingly common and needs to be better understood. She will describe the incidence and patterns of opioid use across different age groups, as well as the morbidity and mortality associated with the use of opioids across the lifespan and associated treatment considerations. Dr. Helen Mayberg will discuss the topic of Deep Brain Stimulation (DBS) for treatment resistant depression (TRD). There has been great excitement following initial positive findings, although more recently there have been inconsistent results in clinical trials. It is important in moving forward to understand these contradictory outcomes. Dr. Mayberg will discuss aspects of DBS and neuromodulation that will impact refinement of treatments in this area. She will address translational aspects of treatment development in this area. Dr. John Mann will present

**Of Special Interest To Clinicians +No CME Credits Offered*

8:15 a.m. - 9:45 a.m.
(continued)

Keynote Plenary: Treatment of Psychiatric Illness Across the Lifespan
Salon 3

on suicide, a crucial public health topic, and discuss implications across the lifespan. He will discuss how suicidal ideation and behavior evolves with age, and he will discuss emerging knowledge of specific risk factors. This information is critical in the development of prevention strategies for different age groups.

8:15 a.m. - 8:30 a.m.

Introduction

8:30 a.m. - 8:55 a.m.

Opioid Use Across the Lifespan

Sandra Comer, Columbia University & New York State Psychiatric Institute

8:55 a.m. - 9:20 a.m.

Strategies to Refine and Optimize DBS for Depression: A Multidisciplinary Translational Approach

Helen Mayberg, Icahn School of Medicine at Mount Sinai

9:20 a.m. - 9:45 a.m.

Suicidal Behavior Across the Life Cycle

J. John Mann, Columbia University

9:45 a.m. - 10:00 a.m.

Break
Americana Foyer

10:00 a.m. - 12:30 p.m.

Federal Agency Directors Plenary
Salon 3

Chair: Michael Thase, Perelman School of Medicine at the University of Pennsylvania

10:00 a.m. - 10:05 a.m.

Introduction

10:05 a.m. - 10:25 a.m.

NIAAA Update

Lorenzo Leggio, National Institute on Alcohol Abuse and Alcoholism

10:25 a.m. - 10:45 a.m.

Research Priorities of NIDA's Medications Development Program

Iván Montoya, National Institute on Drug Abuse

10:00 a.m. - 12:30 p.m. (continued)	Federal Agency Directors Plenary <i>Salon 3</i>
10:45 a.m. - 11:05 a.m.	NIMH Updates and Research Priorities Shelli Avenevoli, National Institute of Mental Health
11:05 a.m. - 11:25 a.m.	VA Research Priorities for Psychopharmacologic Treatments of Mental Disorders Lori Davis, Veterans Affairs Medical Center
11:25 a.m. - 11:45 a.m.	Department of Defense Military Operational Medicine Research Program Ronald Hoover, Department of Defense
11:45 a.m. - 12:30 p.m.	Discussion and Q&A
12:30 p.m. - 1:30 p.m.	ASCP Curriculum Committee Meeting (Invitation Only) <i>Venus</i>
12:30 p.m. - 2:00 p.m.	Early Career Networking Tables (Open to all attendees) <i>Americana Foyer</i>
12:30 p.m. - 2:00 p.m.	Poster Session II with Lunch+ <i>Salon 4</i> <i>See pages 84-94 for a complete listing of posters.</i>
2:00 p.m. - 3:30 p.m.	Clinical Updates in Psychopharmacology* <i>Salon 3</i>

Chair: Holly Swartz, University of Pittsburgh School of Medicine

The purpose of this symposium is to provide an overview of the recent advances in clinical psychopharmacology leading to the development of novel treatments for mood disorders. The session will focus on sexual dysfunction, pharmacogenetics, and ADHD.

2:00 p.m. - 2:30 p.m. **Pathophysiology, Assessment, and Treatment of Sexual Dysfunction**
Anita Clayton, University of Virginia

2:00 p.m. - 3:30 p.m. (continued) **Clinical Updates in Psychopharmacology***
Salon 3

2:30 p.m. - 3:00 p.m. **Which Pharmacogenomic Tests are Useful for Predicting and Reducing Adverse Effects?**
Rajnish Mago, Simple and Practical Mental Health

3:00 p.m. - 3:30 p.m. **Update on Treating ADHD**
Anthony Rostain, Department of Psychiatry, University of Pennsylvania

3:30 p.m. - 3:45 p.m. **Break**
Americana Foyer

Workshops

3:45 p.m. - 5:45 p.m. **Challenges and Implementation of CNS Clinical Trials**
Poinciana 1-2

Chair: John Newcomer, Charles E. Schmidt College of Medicine, Florida Atlantic University

3:45 p.m. - 3:50 p.m. **Introduction**

3:50 p.m. - 4:10 p.m. **Diagnostic and Assessment Challenges in the Design and Conduction of Clinical Trials**
John Kane, The Zucker Hillside Hospital

4:10 p.m. - 4:30 p.m. **A Telemedicine Proof of Concept Study Evaluating the Remote Detection of Alzheimer's Disease and Categorization of Severity**
Penny Randall, IQVIA

4:30 p.m. - 4:50 p.m. **Becoming More Clever, Inclusive, and Broader with Patient Selection including Relying on Data for Patient Selection and Matching Sites**
Daniel Burch, PPD

4:50 p.m. - 5:10 p.m. **Placebo Response and Expectancy**
George Papakostas, Massachusetts General Hospital

5:10 p.m. - 5:45 p.m. **Discussion**

**Of Special Interest To Clinicians +No CME Credits Offered*

3:45 p.m. - 5:45 p.m. **Women's Mental Health Across the Lifespan: Knowledge Gained and Evidence Gaps***
Poinciana 3-4

Chair: Susan Kornstein, Virginia Commonwealth University
Co-Chair: Lee Cohen, Massachusetts General Hospital

3:45 p.m. - 4:05 p.m. **Update on the Genetic Basis of Postpartum Depression**
Jennifer Payne

4:05 p.m. - 4:25 p.m. **Treating Depression and Bipolar Illness in Pregnancy: Knowns and Unknowns**
Lee Cohen, Massachusetts General Hospital

4:25 p.m. - 4:45 p.m. **Risk of Depressive Relapse in Women Pursuing Infertility Treatment**
Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

4:45 p.m. - 5:05 p.m. **New Guidelines for Evaluation and Treatment of Depression in the Menopause Transition**
Susan Kornstein, Virginia Commonwealth University

5:05 p.m. - 5:25 p.m. **Hypoactive Sexual Desire Disorder: An Algorithm for Assessment and Intervention**
Anita Clayton, University of Virginia

5:25 p.m. - 5:45 p.m. **Discussion**

3:45 p.m. - 5:45 p.m. **Behavioral and Psychological Symptoms of Dementia: Perspectives in Clinical Development from the Division of Psychiatry Products, Food and Drug Administration***
Salon 1

Chair: Javier Muniz, Food and Drug Administration

Co-Chair: Juliette Toure, Center for Drug Evaluation and Research, Food and Drug Administration

Discussant: Mitchell Mathis, FDA

3:45 p.m. - 3:55 p.m. **Introduction**

3:55 p.m. - 4:15 p.m. **Behavioral and Psychological Symptoms of Dementia: Assessing Caregiver Burden as a Treatment Outcome**

Wen-Hung Chen, Center for Drug Evaluation and Research, Food and Drug Administration

4:15 p.m. - 4:35 p.m. **Behavioral and Psychological Symptoms of Dementia: Treatment of Agitation**

Nancy Dickinson, FDA

4:35 p.m. - 4:55 p.m. **Apathy in Dementia: A Clinically Meaningful Treatment Target?**

Jean Kim, FDA/CDER/DPP

4:55 p.m. - 5:15 p.m. **Dementia-Related Psychosis: A Regulatory Perspective**

Bernard Fischer, U.S. Food and Drug Administration

5:15 p.m. - 5:35 p.m. **Benefit-Risk Determination for Treatments of Behavioral and Psychological Symptoms of Dementia**

Michael Davis, US Food and Drug Administration

5:35 p.m. - 5:45 p.m. **Discussion**

3:45 p.m. - 5:45 p.m. **Leadership Skills for Mid-Career Professionals**
Salon 2

Chair: Mark Rapaport, Emory University School of Medicine

Discussant: Lori Davis, Veterans Affairs Medical Center

3:45 p.m. - 4:05 p.m. **Introduction**

4:05 p.m. - 5:05 p.m. **Leaders at All Levels: A Mid-Career Leadership
and Career Mentoring Workshop**

Peter Topping, Goizueta Business School, Emory
University

5:05 p.m. - 5:45 p.m. **Discussion**

AT-A-GLANCE

Friday, June 1, 2018

- 7:30 a.m. - 12:00 p.m. **Registration**
Rotunda East
- 7:30 a.m. - 10:30 a.m. **Speaker Ready Room**
Sundial
- 7:30 a.m. - 9:00 a.m. **Morning Break**
Americana Foyer
- 8:30 a.m. - 10:00 a.m. **Panel Sessions**

Optimizing Signal Detection in Psychiatric Clinical Trials	Challenges in Translating Suicidality Concepts for International Trials Across the Lifespan	Neuroplasticity and Ketamine Response in Depression	Controversies in Bipolar Depression Across the Lifespan*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

- 10:00 a.m. - 10:15 a.m. **Break**
Americana Foyer
- 10:15 a.m. - 11:45 a.m. **Regulatory Wrap-Up Plenary**
Salon 3
- 12:00 p.m. **Meeting Adjourns**

Friday

FULL SCHEDULE

Friday, June 1, 2018

7:30 a.m. - 12:00 p.m. **Registration**
Rotunda East

7:30 a.m. - 10:30 a.m. **Speaker Ready Room**
Sundial

7:30 a.m. - 9:00 a.m. **Morning Break**
Americana Foyer

Panel Sessions

8:30 a.m. - 10:00 a.m. **Optimizing Signal Detection in Psychiatric
Clinical Trials**
Poinciana 1-2

Chair: George Papakostas, Massachusetts General Hospital

Co-Chair: Maurizio Fava, Massachusetts General Hospital

Discussant: Maurizio Fava, Massachusetts General Hospital

8:30 a.m. - 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. **Selecting Participants for Clinical Trials: How to
Recruit the Best Participants**
Madhukar Trivedi, UT Southwestern Medical Center

9:00 a.m. - 9:20 a.m. **Optimizing Signal Detection in Antidepressant
Clinical Trials: Role of Blinding and Masking+**
William Martin, Alkermes, Inc.

9:20 a.m. - 9:40 a.m. **How Site Selection and Geographic Factors Can
Affect Signal Detection (and What Might be Done
About it)**
Michael E. Thase, Perelman School of Medicine at
the University of Pennsylvania

9:40 a.m. - 10:00 a.m. **Optimizing Psychiatric Clinical Trial Outcomes:
The Role of Subject and Rater Expectations**
George Papakostas, Massachusetts General
Hospital

**Of Special Interest To Clinicians +No CME Credits Offered*

8:30 a.m. - 10:00 a.m. Challenges in Translating Suicidality Concepts for International Trials Across the Lifespan
Poinciana 3-4

Chair: Sofija Jovic, MedAvante-ProPhase, Inc.

Discussant: Jennifer Giddens, University of South Florida

8:30 a.m. - 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. **Challenges in Translating Suicidality Concepts**
David Sheehan, University of South Florida College of Medicine

9:00 a.m. - 9:20 a.m. **Linguistic Validation of a Pediatric Suicidality Scale Within a Single Language**
Darlene Amado, University of South Florida

9:20 a.m. - 9:40 a.m. **The Process and Challenges of International Linguistic Validation of the Sheehan Suicidality Tracking Scale**
Caroline Anfray, Mapi Research Trust

9:40 a.m. - 10:00 a.m. **Discussion**

8:30 a.m. - 10:00 a.m. Neuroplasticity and Ketamine Response in Depression
Salon 1

Chair: Lawrence Park, NIMH/NIH

Discussant: Lawrence Park, NIMH/NIH

8:30 a.m. - 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. **Neuroinflammation and Synaptic Plasticity: Does Ketamine Treatment Modulate the Crosstalk?**
Bashkim Kadriu, National Institute of Mental Health

9:00 a.m. - 9:20 a.m. **Biomarkers of Ketamine's Rapid Antidepressant Effects: Focus on Neuroplasticity**
Rodrigo Machado-Vieira, University of Texas Health Science Center at Houston

8:30 a.m. - 10:00 a.m. **Neuroplasticity and Ketamine Response in Depression**
(continued) *Salon 1*

9:20 a.m. - 9:40 a.m. **Measuring Neuroplasticity in the DLPFC Using TMS Combined With EEG**
 Zafiris Daskalakis, CAMH

9:40 a.m. - 10:00 a.m. **Distinct Behavioral and Electrophysiological Effects of Ketamine in Depressed Patients and Healthy Volunteers**
 Allison Nugent, Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, DHHS

8:30 a.m. - 10:00 a.m. **Controversies in Bipolar Depression Across the Lifespan***
Salon 2

Chair: Scott Aaronson, Sheppard Pratt Health System

Discussant: Mark Rapaport, Emory University School of Medicine

8:30 a.m. - 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. **More Childhood Onset Bipolar Disorders in the U.S.: What You Need to Know and Do**
 Robert Post, Bipolar Collaborative Network

9:00 a.m. - 9:20 a.m. **Antidepressants to Be or Not to Be: When in Bipolar Depression Should We Use Them?**
 Terence Ketter, Stanford University

9:20 a.m. - 9:40 a.m. **Transcranial Magnetic Stimulation and Vagus Nerve Stimulation in the Acute and Chronic Management of Bipolar Depression**
 Scott Aaronson, Sheppard Pratt Health System

9:40 a.m. - 10:00 a.m. **Bipolar Depression in Older Adults**
 Martha Sajatovic, University Hospitals Case Medical Center

10:00 a.m. - 10:15 a.m. **Break**
Americana Foyer

**Of Special Interest To Clinicians +No CME Credits Offered*

**10:15 a.m. - 11:45 a.m. Regulatory Wrap-Up Plenary
Salon 3**

Chair: John Newcomer, Charles E. Schmidt College of Medicine, Florida Atlantic University

Speakers: Tiffany Farchione, US Food and Drug Administration
Mitchell Mathis, US Food and Drug Administration
Valentina Mantua, AIFA

12:00 p.m. Meeting Adjourns




Wednesday, May 30, 2018

Poster Session I with Lunch

11:15 a.m. - 1:00 p.m.

Salon 4

- W1. Effects of Suvorexant on 35% CO₂-Induced Panic: A Pilot Study**
 Andrew Goddard, UCSF Fresno
 Andrew Goddard*, David Mazariegos, Barbara Price, Rebekah Garcia,
 Tim Tyner
- W2. Meta-Analysis of Prenatal Antidepressant Exposure as Risk Factor for Autism: Impact of Comparison Group Definition**
 Monica Vega, Jackson Memorial Hospital/ UM
 Monica Vega*, Graham Newport, Durim Bozhdaraj, Samantha Saltz,
 Charles Nemeroff, Donald J. Newport
- W3. Anterior Cingulate Cortical Glutamate and Excitatory Amino Acid Transporter 2 (EAAT2) Genetic Variation in Patients With Depression**
 Marin Veldic, Mayo Clinic, Mayo Clinic Depression Center
 Marin Veldic*, John Port, Man Choi (Ada) Ho, Yun-Fang Jia, Jennifer Geske, Joanna Biernacka, Doo-Sup Choi, Mark Frye
-  **W4. An Epigenetic Biomarker for Depression and Trait of Childhood Trauma With Sex-Specific Effects**
 Carla Nasca, The Rockefeller University
 Carla Nasca*, Betty Bigio, Sarah Young, James Kocsis, Francis Lee,
 James Murrough, Natalie Rasgon, Bruce McEwen
- W5. Plasma Tumor Necrosis Factor-Alpha Correlates With L-Selectin in Patients With Schizophrenia**
 Shiva Sharma, University of Texas Harris County Psychiatric Center
 Shiva Sharma*, Satyajit Mohite, Savitha Kumari Satyasi, Sharon Karki,
 Olaoluwa Okusaga
- W6. Characteristics of Patients in Recovery Versus Patients With Recurrence in a Randomized Placebo-Controlled Study With Aripiprazole Once-Monthly as Maintenance Treatment for Bipolar I Disorder**
 Jessica Madera, Otsuka Pharmaceutical Development &
 Commercialization, Inc.
 Jessica Madera*, Pedro Such, Peter Zhang, Ross Baker



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- W7. Remission and Recovery in Patients With Bipolar I Disorder (BP-I) Treated With Aripiprazole Once-Monthly (AOM 400)**
Heather Fitzgerald, Lundbeck
Jessica J. Madera, Na Jin, Joan Amatniek, Brian R. Johnson, Ross Baker, Heather Fitzgerald*, Pedro Such
- W8. Demographic and Clinical Comparison of Patients With Bipolar Disorder on Lithium Versus Lamotrigine Maintenance Treatment**
Balwinder Singh, Mayo Clinic
Balwinder Singh*, Colin Colby, Susan McElroy, David Bond, Marin Veldic, Miguel Prieto, Alfredo Cuellar-Barboza, Joanna Biernacka, Mark Frye
- W9. Effect on Functioning With Aripiprazole Once-Monthly (AOM 400) in the Long-Term Treatment of Bipolar I Disorder**
Maxine Chen, Otsuka Pharmaceutical Development & Commercialization, Inc.
Jessica J. Madera, Na Jin, Pedro Such, Brian R. Johnson, Maxine Chen*, Ross Baker
- W10. Development Update on Pimavanserin, a Novel 5-HT_{2A} Receptor Inverse Agonist**
James Owen, Acadia Pharmaceuticals, Inc.
James Owen*, Bryan Dirks, James Youakim, Dragana Bugarski-Kirola, Doral Fredericks, Srdjan Stankovic
- W11. ADHD and Chronic Anhedonia as Predictors of Treatment Response and Suicidality in Individuals With Generalization Anxiety Disorder**
Tia Sternat, START Clinic for Mood and Anxiety Disorders
Tia Sternat*, Kathryn Fotinos, Alexa Fine, Catherine Cameron, Irvin Epstein, Martin Katzman
- W12. A Double-Blind, Placebo-Controlled, Dose-Ranging Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD**
Marina Lowen, Supernus Pharmaceuticals, Inc.
Tesfaye Liranso, Keith Saylor, Scott Brittain, Gabriela Tulloch, Marina Lowen*
- W13. Improvement in ADHD-Related Symptoms and Behaviors in Children With ADHD Treated With Dasotraline: Results of a Post-Hoc ADHD-RS-IV Item Analysis**
Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
Robert Goldman, Andrei Pikalov*, Jay Hsu, Antony Loebel



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W14. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: Results of a 12-Week Open-Label Extension Study


Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Stephen Stahl, Andrei Pikalov*, Michael Tocco, Yongcai Mao, Antony Loebel

W15. Inflammatory Markers and Cognitive Performance in Patients With Schizophrenia Treated With Lurasidone

Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Andrei Pikalov*, Brian Miller, Cynthia Siu, Michael Tocco, Joyce Tsai, Philip Harvey, Antony Loebel

W16. Efficacy of Lurasidone in Child and Adolescent Patients With Bipolar I Depression and Anxiety: A Post-Hoc Analysis

Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Mark S. Owens, Andrei Pikalov*, Michael Tocco, Ling Deng, Robert Goldman, Antony Loebel

 **W17. Neural Reactivity to Reward as a Predictor of Depressive Symptom Change in Youth Following SSRI and CBT Treatment**

Katie Burkhouse, University of Illinois at Chicago
 Katie Burkhouse*, Kate Fitzgerald, Christopher Monk, K. Luan Phan

W18. Safety and Effectiveness of Long-Term Treatment With Lurasidone in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-Year Open-Label Extension Study

Michael Tocco, Sunovion
 Robert Goldman, Melissa DelBello, Katherine E. Burdick, Michael Tocco*, Andrei Pikalov, Ling Deng, Antony Loebel

W19. Task Engagement During Unsupervised Computerised Cognitive Testing: Impact of Self-Reported Mental Health Issues

Francesca Cormack, Cambridge Cognition
 Francesca Cormack*, Nick Taptiklis, Jennifer Barnett

W20. Submission Withdrawn

W21. Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

Zev Nakamura, University of North Carolina at Chapel Hill
 Zev Nakamura*, Allison Deal, Stephanie Chien, Eliza Park, William Wood, Thomas Shea, Donald Rosenstein



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W22. Feasibility of an Electronic Version of the Overt Aggression Scale, Modified (OAS-M) in the Measurement of Intermittent Explosive Disorder Symptoms: Correspondence of Paper and Electronic Versions

Joan Busner, Bracket Global, LLC

Joan Busner*, Emil Coccaro, Samantha Silverman, Jean Dries, Margot Oakley, John Gorman, Alan Kott, Xingmei Wang

W23. Successful Lifespan-Targeted Patient Recruitment Strategies for Outpatient Psychiatric and Neurological Clinical Trials

Charles Wilcox, Pharmacology Research Institute

Charles Wilcox*, Nader Oskooilar, Judy Morrissey, David Rosenberg, My-Linh Tong, Mellissa Henry, Daniel Grosz

W24. A Double-Blinded, Placebo-Controlled RCT of Repeated Daily Sessions of Transcranial Direct Current Stimulation (tDCS) for the Affective Symptoms of Chronic Low Back Pain (CLBP)

Timothy Mariano, Harvard Medical School

Timothy Mariano*, Frederick Burgess, Marguerite Bowker, Jason Kirschner, Mascha van't Wout-Frank, Richard Jones, Christopher Halladay, Michael Stein, Benjamin Greenberg

W25. A Meta-Analysis of the Neurocognitive Functioning in Cannabis-User and Non-User Patients With First-Episode Psychosis

Teresa Sanchez-Gutierrez, Universidad Internacional de La Rioja

Teresa Sanchez-Gutierrez*, Belén Fernandez-Castilla, Sara Barbeito, Juan Antonio Becerra, Ana Calvo

*** W26. The GABA-A Receptor Positive Allosteric Modulators Brexanolone IV and SAGE-217 in the Treatment of Mood Disorders: Results From Recent Placebo-Controlled Studies**

Stephen Kanés, Sage Therapeutics

Stephen Kanés*, Samantha Meltzer-Brody, Handan Gunduz-Bruce, Abdul Sankoh, Haihong Li, Ella Li, Helen Colquhoun, David Rubinow, Charles Zorumski, James Doherty, Jeffrey Jonas

*** W27. Clinical Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray in U.S. Geriatric Patients With Treatment-Resistant Depression**

Lynn Starr, Janssen Scientific Affairs, LLC

Lynn Starr*, Rachel Ochs-Ross, Yun Zhang, Pilar Lim, Rosanne Lane, Allitia DiBernardo, May Shawi, David Hough, Larry Alphs, Jaskaran Singh



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

- * W28. Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients With Major Depressive Disorder**
James Murrough, Icahn School of Medicine at Mount Sinai
Aaron Tan, Sara Costi, Laurel Morris, Nicholas Van Dam, Marin Kautz, Alexis Whitton, Allyson Friedman, Katherine Collins, Gabriella Ahle, Diego Pizzagalli, Dan Iosifescu, Eric Nestler, Ming-Hu Han, James Murrough*
- W29. Onabotulinumtoxin A for the Treatment of Major Depressive Disorder in Women: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial**
Susan Kornstein, Virginia Commonwealth University
Suresh Durgam, Mitchell Brin, Arlene Lum, Lynn James, Jeen Liu, Michael E. Thase, Susan Kornstein*, Armin Szegedi
- * W30. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression**
Vanina Popova, Janssen Pharmaceutical Companies of JNJ
Vanina Popova*, Ella Daly, Madhukar Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, David Hough, Michael E. Thase, Richard Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini Manji, Wayne C. Drevets, Jaskaran Singh
- W31. ALKS 5461 (a Buprenorphine-Samidorphane Combination) for Adjunctive Treatment of Major Depressive Disorder: Results From Analyses of U.S. Patients From Three Placebo-Controlled Trials**
Maurizio Fava, Massachusetts General Hospital
Maurizio Fava*, Michael E. Thase, Madhukar Trivedi, Sanjeev Pathak, Arielle Stanford, Asli Memisoglu, William Martin, Amy Claxton, Elliot Ehrich
- W32. Gender Differences in Response to and Tolerability of Ketamine as a Treatment for Acute Depression**
Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health
Marlene Freeman*, George Papakostas, Bettina Hoepfner, Erica Mazzone, Heidi Judge, Cristina Cusin, Sanjay Mathew, Gerard Sanacora, Dan Iosifescu, Madhukar Trivedi, Maurizio Fava



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W33. The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure to Lurasidone on Risk for Major Malformations

Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

Marlene Freeman*, Adele Viguera, Alexandra Sosinsky, Taylor Church, Sara McElheny, Sonia Hernández-Díaz, Lee Cohen

W34. Long-Term Efficacy, Safety, and Tolerability of Adjunctive ALKS 5461 in Patients With Major Depressive Disorder Enrolled in an Ongoing Phase 3 Study

Michael E. Thase, Perelman School of Medicine at the University of Pennsylvania

Michael E. Thase*, Arielle D. Stanford, Asli Memisoglu, William Martin, Amy Claxton, J. Alexander Bodnik, Madhukar Trivedi, Maurizio Fava, Sanjeev Pathak

W35. Assessment in Work Productivity and the Relationship With Cognitive Symptoms (AtWoRC): Final Analysis From a Canadian Open-Label Study of Vortioxetine in First Treatment and Switch Patients With Major Depressive Disorder

Jean Proulx, Lundbeck Canada

Pratap Chokka, Joanna Bougie, Jean Proulx*

W36. A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound, Among Outpatients With Major Depressive Disorder

George Papakostas, Massachusetts General Hospital

George Papakostas*, Karl Johe, Holly Hand, Amy Drouillard, Priscilla Russo, Gary Kay, Bettina Hoepfner, Martina Flynn, Albert Yeung, Rutendo Kashambwa, Maurizio Fava

W37. A Systematic Review of Psilocybin in the Treatment of Depression and Anxiety

Trisha Suppes, Stanford University

Trisha Suppes*, Jihun Lyu, Benjamin Hambro

W38. Electroencephalographic Parameters During Electroconvulsive Therapy: Relationship to Clinical Response

Ahmed Makhoulf, Mayo Clinic

Ahmed Makhoulf*



= New Investigator Awardee




= Pharmaceutical Pipeline Presentation

W39. Components and Trends in Treatment Effects in Randomized Placebo-Controlled Trials in Major Depressive Disorder 1979-2016

Marc Stone, FDA/CDER/DPP

Marc Stone*, Brian Miller, Shamir Kalaria, Kyle Richardville

 **W40. Withania Somnifera and Schizophrenia: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of an Adjunctive Treatment for Mood and Negative Symptoms**

Jessica Gannon, University of Pittsburgh School of Medicine

Jessica Gannon*

W41. Clinical Evaluation of Abuse Potential of ALKS 5461

Sanjay Mathew, Baylor College of Medicine

Sanjay Mathew*, Andrew J. Cutler, Beatrice Setnik, Narinder Nangia, Arielle D. Stanford, Sanjeev Pathak

W42. Cannabidiol: A Novel Neuromodulatory Pharmacological Intervention to Treat Neuropsychiatric Disorders

Jose Crippa, University of Sao Paulo

Jose Crippa*

W43. Do Multiple Psychiatric Diagnosis in Smokers Affect Their Dependence and Withdrawal From Nicotine?

Ahmad Hameed, Penn State College of Medicine

Ahmad Hameed*, Susan Valdheer, Emily Wasserman, Usman Hameed, Jonathan Foulds

W44. The Evaluation of Adherence to Treatment and Real-World Outcomes in Two Cohorts of Patients With Serious Mental Illness (SMI)

Felicia Forma, Otsuka Pharmaceutical Development & Commercialization, Inc.

Felicia Forma*, Christie Teigland, Seung Kim, Teresa Green

W45. Dasotraline for Treatment of Adults With Binge-Eating Disorder: Effect on Behavioral Outcomes

Bradford Navia, Sunovion Pharmaceuticals, Inc.

Bradford Navia*, James Hudson, Susan McElroy, Ling Deng, Seth C. Hopkins, Kenneth S. Koblan, Antony Loebel, Robert Goldman

W46. Teaching and Practice of Clinical Psychopharmacology

Ira Glick, Stanford University School of Medicine


Ira Glick*, Driss Moussaoui



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- W47. Brief History of Clinical Psychopharmacology in China**
Yifeng Shen, Shanghai Mental Health Center
Yifeng Shen*, Huafang Li
- * W48. Efficacy and Safety of MIN-101: A New Compound for the Treatment of Negative Symptoms in Schizophrenia a 12-Week Randomized, Double Blind, Placebo-Controlled Trial**
Michael Davidson, Tel-Aviv University
Michael Davidson*, Jay Saoud, Corinne Staner, Remy Luthringer
- W49. Digital Phenotyping in Schizophrenia: Do Clinical Assessments Matter Anymore?**
William Yavorsky, Cronos CCS
William Yavorsky*, Nina Engelhardt, Cynthia McNamara, Kristy Wolanski, Francisco Burger, Guillermo DiClemente
- W50. Long-Term Outcomes With Aripiprazole Lauroxil for the Treatment of Schizophrenia: A 2-Year, Phase 3, Multicenter Extension Study**
John Lauriello, University of Missouri
John Lauriello*, Amy Claxton, Yangchun Du, Peter Weiden
- * W51. A Proof-Of-Mechanism Study of the PDE10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms Probing Reward Functions With Imaging and Behavioral Approaches**
Daniel Umbricht, F. Hoffmann-La Roche Ltd
Daniel Umbricht*, Jürgen Dukart, Markus Abt, Paul Tamburri, Chris Chatham, Michael Frank, Anne Collins, David Walling, Rick Mofsen, Daniel Gruener, Lev Gertsik, Jeff Sevigny
- W52. Treatment Patterns and Healthcare Resource Utilization Among Young Adults With Schizophrenia Treated With Paliperidone Palmitate or Oral Atypical Antipsychotics**
Tony Amos, Janssen Scientific Affairs, LLC
Tony Amos*, Antoine El Khoury, Anna Vlahiotis, Janna Manjeliavskaia, Ashley Cole, Paul Juneau
-  W53. Utility of MRI in Investigating Antipsychotic-Induced Metabolic Abnormalities: A Pilot Study**
Araba Chintoh, Centre for Addiction and Mental Health
Araba Chintoh*, Sri Mahavir Agarwal, Nicole MacKenzie, Gary Remington, Margaret Hahn



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

W54. Lumateperone Improves Negative Symptoms Related to Emotional Experience in Patients With Schizophrenia

Philip Harvey, University of Miami Miller School of Medicine
Philip Harvey*, Kimberly Vanover, Michal Weingart, Robert Davis, Alex Dmitrienko

W55. Efficacy and Safety of Lurasidone in Adolescents With Schizophrenia: Interim Analysis of a 2-Year, Open-Label Extension Study

Robert Goldman, Sunovion Pharmaceuticals, Inc.
Robert Goldman*, Michael Tocco, Andrei Pikalov, Ling Deng, Antony Loebel

W56. Effects of Tardive Dyskinesia on Eye Movement Measures in Treatment-Resistant Schizophrenia

Jane Stocks, Northwestern University, Feinberg School of Medicine
Jane Stocks*, Tatiana Karpouzian, Herbert Meltzer, James Reilly

W57. The Impact of Second-Generation Antipsychotic Medication Side-Effects on Functioning From a Schizophrenia Patient Perspective: A Cross-Sectional, Observational, Patient Centered, Web Survey Study



Catherine Weiss, Otsuka Pharmaceutical Development & Commercialization, Inc.
Catherine Weiss*, Laëtitia Bouérat Duvold, William R. Lenderking, Owen Cooper, Huda Shalhoub, Leah Kleinman, Randall Bender, Anne Hartry, Mallik Green, Stine R. Meehan, Rajiv Tandon


W58. Amotivation is Associated With Smaller Ventral Striatum Volumes in Older Patients With Schizophrenia Independently of Antipsychotic Occupancy of Dopamine D2 Receptors

Fernando Caravaggio, Centre for Addiction and Mental Health
Fernando Caravaggio*, Gagan Fervaha, Yusuke Iwata, Eric Plitman, Jun Ku Chung, Shinichiro Nakajima, Wanna Mar, Philip Gerretsen, Julia Kim, Mallar Chakravarty, Benoit H. Mulsant, Bruce Pollock, David Mamo, Gary Remington, Ariel Graff-Guerrero

 **W59. Long-Acting Atypical Antipsychotics and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analyses**

Andrew Olagunju, The University of Adelaide
Andrew Olagunju*, Scott Clark, Bernhard Baune

 = New Investigator Awardee  = Pharmaceutical Pipeline Presentation

-  **W60. Galantamine and Memantine Combination Targets Triple Hypotheses in Schizophrenia: Will This end D2 me too?**
Maju Koola, George Washington University, School of Medicine and Health Sciences
Maju Koola*
- W61. Paroxetine, But Not Vortioxetine, Impairs Sexual Functioning Compared to Placebo in Healthy Adults**
Paula Jacobsen, Takeda Development Center Americas, Inc.
Paula Jacobsen*, Wei Zhong, George Nomikos, Anita Clayton
- W62. Elements of Desire Questionnaire Assessment of Bremelanotide Efficacy for Hypoactive Sexual Desire Disorder in the RECONNECT Study**
Dennis Revicki, Evidera
Dennis Revicki*, Stanley Althof, Leonard DeRogatis, Sheryl Kingsberg, Hilary Wilson, Robert Jordan, Johna Lucas
- W63. The Effect of Prenatal Exposure to Atypical Antipsychotics on Child Development and Behavior**
Carol Swetlik, Cleveland Clinic Lerner College of Medicine
Carol Swetlik*, Adele Viguera, Marlene Freeman, Alexandra Sosinsky, Taylor Church, Sara McElheny, Lee Cohen
- W64. The National Pregnancy Registry for Psychiatric Medications: Effects of Fetal Exposure to Atypical Antipsychotics on Risk for Major Malformations**
Adele Viguera, Cleveland Clinic
Adele Viguera*, Marlene Freeman, Alexandra Sosinsky, Taylor Church, Sara McElheny, David Chitayat, Sonia Hernández-Díaz, Lee Cohen
- W65. Reliability and Validity of a Self-Report Scale for Daily Assessments of the Severity of Depressive Symptoms**
Mark Zimmerman, Brown University
Mark Zimmerman*, Lourn Harris, Jacob Martin, Patrick McGonigal
- W66. Dasotraline for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: Pooled Analysis of Two Double-Blind Studies**
Joyce Tsai, Sunovion Pharmaceuticals, Inc.
Lenard A. Adler, Scott H. Kollins, Seth C. Hopkins, Robert Goldman, Joyce Tsai*, Jay Hsu, Andrei Pikalov, Kenneth S. Koblan, Antony Loebel
- W67. Using Computer Vision and Machine Learning to Identify Patterns of Fraudulent Participant Activity in CNS Trials**
Adam Hanina, AiCure
Adam Hanina*, Laura Shafner, Ryan Bardsley



= New Investigator Awardee



* = Pharmaceutical Pipeline Presentation

W68. A Randomized Withdrawal, Double-Blind, Multicenter Study of Esketamine Nasal Spray Plus an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression

Ella Daly, Johnson & Johnson PRD

Ella Daly*, Jaskaran Singh, Madhukar Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna Duca, David Hough, Michael E. Thase, John Zajecka, Andrew Winokur, Ilona Divacka, Andrea Fagiolini, Wieslaw Cubala, Istvan Bitter, Pierre Blier, Richard Shelton, Patricio Molero, Hussein Manji, Wayne C. Drevets

W69. Inaccurate Prescribing Warnings in Electronic Medical Record Systems: Results From an American Society for Clinical Psychopharmacology Membership Survey

Katharine Phillips, Weill Cornell Medical College/NewYork-Presbyterian Hospital

Katharine Phillips*, Leslie Citrome



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

Thursday, May 31, 2018**Poster Session II with Lunch**

12:30 p.m. - 2:00 p.m.

Salon 4

- * T1. Lofexidine for Treatment of Opioid Withdrawal Symptoms: A Double-Blind, Placebo-Controlled, Multicenter Trial in Opioid-Dependent Subjects**
Danesh Alam, Northwestern Medicine Central Dupage
Danesh Alam*, Mark Pirner, Thomas Clinch, Marc Fishman
- T2. Duration of Opioid Use Disorder is Associated With Prolonged Sleep Latency in Subjects With Opioid Use Disorder on Buprenorphine**
Venkatesh Krishnamurthy, Penn State Milton S. Hershey Medical Center
Venkatesh Krishnamurthy*, Alissa Coffey, Sanjay Yadav, Jatinder Singh, Lan Kong, Alexndros Vgontzas, Edward Bixler, Roger Meyer
-  **T3. Psychiatric and Non-Psychiatric Implications of Substance Use Disorders in Older Adults**
Sabrina Correa da Costa, The University of Texas Health Science Center at Houston
Sabrina Correa da Costa*, Antonio L. Teixeira, Breno Satler de Oliveira Diniz, Scott D. Lane
-  **T4. Premature Discharge From Medication-Assisted Treatment (MAT) for Opioid Dependence: A Multi-Site Naturalistic Comparison of Buprenorphine vs. Methadone**
Steven Proctor, Albizu University
Steven Proctor*, Philip Herschman
-  **T5. Determining Human Brain Modular Architecture Using Subject-Level Functional Networks**
Teddy Akiki, Yale University
Teddy Akiki*, Chadi Abdallah
- T6. Inflammatory Correlates of Specific Symptoms of Depression**
Marzieh Majd, Pennsylvania State University
Marzieh Majd*, Jody Greaney, Erika Saunders, Christopher G. Engeland



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- T7. Effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder**
David Fleck, University of Cincinnati College of Medicine
David Fleck*, James Eliassen, Anna I. Guerdjikova, Stephanie Williams, Thomas Blom, Travis Beckwith, Maxwell Tallman, Susan McElroy
- T8. Assessment of Functional Recovery After Long-Term Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder**
Jessica Madera, Otsuka Pharmaceutical Development & Commercialization, Inc.
Jessica Madera*, Pedro Such, Peter Zhang, Ross Baker
- T9. The Impact of Obesity on Pregnancy Outcomes Among Women With Psychiatric Disorders**
Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health
Marlene Freeman*, Lee Cohen, Adele Viguera, Lina Goetz-Mogollon, Alexandra Sosinsky, Taylor Church, Sara McElheny, David Chitayat, Sonia Hernández-Díaz
- T10. The Impact of Adherence Information on Provider Decisions in Treating Bipolar and Major Depressive Disorders**
Felicia Forma, Otsuka Pharmaceutical Development & Commercialization, Inc.
Charles Ruetsch, Jennifer Clerie, Tigwa Davis, Felicia Forma*
- T11. A 52-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness of Aripiprazole Once-Monthly as Maintenance Treatment in Patients With Bipolar I Disorder**
Maxine Chen, Otsuka Pharmaceutical Development & Commercialization, Inc.
Joseph Calabrese, Na Jin, Brian R. Johnson, Peter Hertel, Pedro Such, Jocelyn Ottinger, Maxine Chen*, Joan Amatniek
- T12. Technology Use Among Individuals With Serious Mental Illnesses in Community Settings**
Eric Achtyes, Michigan State University College of Human Medicine
Eric Achtyes*, Sarah Pratt, Kellen Stilwell, Michael Opperman, Mary Brunette



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

*** T13. NIMH FAST-MAS Phase IIa Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activation During the Monetary Incentive Delay Test in Anhedonic Patients with Mood and Anxiety Spectrum Disorders**

Andrew Krystal, University of California, San Francisco

Andrew Krystal*, Diego Pizzagalli, Moria Smoski, Sanjay Mathew, John Nurnberger, Sarah Lisanby, Dan Iosifescu, James Murrough, Richard Weiner, Joseph Calabrese, Gerard Sanacora, Richard Keefe, Steven Szabo, Wayne Goodman, William Potter

T14. CRCDS-MiniSim: A Standardized Test for Drug Impaired Driving

Gary Kay, Cognitive Research Corporation

Gary Kay*, Steven Horohonich, Thomas Hochadel

 T15. An Optimization of Aggregated N-Of-1 Trial Design to Predictive Biomarker Validation

Rebecca Hendrickson, VA Puget Sound Health Care System

Rebecca Hendrickson*, Steven Millard, Shofer Jane, Murray Raskind, Nicholas Schork

T16. AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development

Cedric O’Gorman, Axsome Therapeutics, Inc.

Cedric O’Gorman*, Amanda Jones, Kellie Kennon, Herriot Tabuteau

*** T17. The Relationship Between Cognition and Depression Improvement among MDD Patients by NSI-189, a Neurogenic, Pro-Cognitive, Antidepressant Compound**

Karl Johe, Neuralstem, Inc.

Gary Kay, Roger McIntyre, Katherine E. Burdick, Karl Johe*, Santosh Kumar, George Papakostas, Maurizio Fava

 T18. Efficacy of Intravenous Ketamine Treatment on Anxious Versus Non-Anxious Unipolar Treatment-Resistant Depression

Naji Salloum, Harvard Medical School/Massachusetts General Hospital

Naji Salloum*, George Papakostas, Maurizio Fava, Bettina Hoepfner, Martina Flynn, Marlene Freeman, Cristina Cusin, Dan V. Iosifescu, Madhukar Trivedi, Gerard Sanacora, Sanjay Mathew, Charles DeBattista

T19. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital



Samuel Wilkinson, Yale School of Medicine



Samuel Wilkinson*, Brandon Kitay, Ryan Webler, Rachel Katz, Robert Ostroff, Gerard Sanacora



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

- T20. Ketamine Non-Responders Exhibit Pathological Increases in Extracellular Free Water Following Treatment**
 Stefan Peyda, Massachusetts General Hospital, Harvard Medical School
 Stefan Peyda*, Valerie J. Sydnor, Marek R. Kubicki, Suheyla C. Karayumak, Joey Cheung, Julia M. Felicione, Martha E. Shenton, Oluwaseun Akeju-Johnson, Ofer Pasternak, Thilo Deckersbach, Cristina Cusin
-  **T21. Cortical Excitability in Patients With Treatment Resistant Depression Receiving Ketamine**
 Zhi-De Deng, National Institute of Mental Health
 Zhi-De Deng*
- T22. Antidepressant Effects on the Pain Network in Patients With Depression**
 David Hellerstein, Columbia University
 Yun Wang, Joel Bernanke, David Hellerstein*, Bradley Peterson, Jonathan Posner
-  **T23. rs10769025-ALX4 Polymorphism Predicts SSRI Response: COMed Trial Findings Validated in PGC Consortium GWAS Dataset**
 Bharathi Gadad, University of Texas Southwestern Medical Center at Dallas
 Bharathi Gadad*, Prithvi Raj, Manish Jha, Tracy Greer, Thomas Carmody, Edward Wakeland, Madhukar Trivedi
- T24. Pharmacogenomics and Depression Symptom Improvement: Treatment by Primary Care Physicians or Psychiatrists**
 Julie-Anne Tanner, Tanenbaum Pharmacogenetics Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Assurex Health Ltd.
 Julie-Anne Tanner*, Paige E. Davies, Lisa C. Brown, Nicholas C. Voudouris, Bryan M. Dechairo, James L. Kennedy
- T25. Clinical Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray in a U.S. Population of Patients With Treatment-Resistant Depression**
 May Shawi, Johnson & Johnson
 May Shawi*, Vanina Popova, Kimberly Cooper, Lynn Starr, Allitia DiBernardo, Carol Jamieson, David Hough, Jaskaran Singh, Larry Alphas

 = New Investigator Awardee  = Pharmaceutical Pipeline Presentation


- T26. High-Frequency Assessment of Mood and Cognition in Major Depressive Disorder Using the Apple Watch**
Francesca Cormack, Cambridge Cognition
Francesca Cormack*, Maggie McCue, Jen Schuster, Nick Taptiklis, Ellie Panagopoulos, Tempest Van Schaik, Ben Fehner, James King, Jennifer Barnett
- T27. Goal Achievement After a Switch to Vortioxetine in Adults With Major Depressive Disorder (MDD): Interim Study Results**
Maggie McCue, Takeda Pharmaceuticals U.S.A., Inc.
Maggie McCue*, Sagar V. Parikh, Lisa Mucha, Sara Sarkey, Jennifer Schuster, Charlie Cao, Anna Eramo, Clement Francois
- T28. Definitions of Treatment-Resistant Depression: A Narrative and Systematic Review**
Bradley Gaynes, University of North Carolina
Bradley Gaynes*, Gary Asher, Gerald Gartlehner, Valerie Hoffman
- T29. Does Childhood Trauma Impact Outcomes in Adults Receiving Ketamine for Depression?**
Brittany O'Brien, Baylor College of Medicine / Michael E DeBakey VA Medical Center
Brittany O'Brien*, Allison Wells, Marijn Lijffijt, Michelle Davis, Jesse Wells, Alan C. Swann, Sanjay Mathew
- T30. Improving Screening, Access, and Outcomes Through Virtual Behavioral Health Integration Into Primary Care**
Manuel Castro, Carolinas Health Care
Manuel Castro*, Kate Rising
- T31. Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Trials in Schizophrenia**
Ruth A. Duffy, Otsuka Pharmaceutical Development and Commercialization, Inc.
Ruth A. Duffy*, Jelena Ivkovic, Annika Lindsten, Vinu George, Hans Eriksson, Mary Hobart
- T32. Effect of Adjunctive Brexpiprazole on Depressive Symptoms in Elderly Patients With Anxiety or Insomnia: Results From a Post-Hoc Analysis**
Keva Gwin, Lundbeck, LLC
Keva Gwin*, Stine R. Meehan, Nanco Hefting, Doris Zhang, Catherine Weiss, Ross A. Baker




= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- * T33. Moving Beyond Efficacy and Safety to Real-World Usability in the Digital Medicine Era**
 Timothy Peters-Strickland, Otsuka Pharmaceutical Development and Commercialization
 Timothy Peters-Strickland*, Cathy Zhao, Tao Wang, Corey Fowler, Ross A. Baker
-  T34. Adherence to Local Mental Health Center Follow-up Appointments After Discharge From An Acute Psychiatric Hospitalization in a Rural Area**
 Stephanie Phan, University of Georgia College of Pharmacy
 Stephanie Phan*, Henry Young
- T35. Project Starr 911: A Model for Researchers to Engage in Suicide Prevention**
 Jelena Saillard, Intra-Cellular Therapies, Inc.
 Jelena Saillard*, Patrick Hendry, Krista Armstrong, Jessica Barag, Corey Fowler, Nichole Gutierrez, Jill Harkavy-Friedman, Eli Perez, Kimberly Vanover, Luke Kramer
- T36. Are Drug Interaction Warnings Influenced by Drug Company Promotion?**
 Jeffrey Mattes, Psychopharmacology Research Association of Princeton, P.C.
 Jeffrey Mattes*
- T37. Application of Novel Approaches for the Design of Prediction Algorithms for Antidepressant Efficacy and Side-Effects**
 Dekel Taliáz, Taliáz Ltd.
 Dekel Taliáz*
- T38. Population Pharmacokinetics of Valbenazine and its Active Metabolite**
 Gordon Loewen, Neurocrine Biosciences, Inc.
 Gordon Loewen*, Jace Nielsen, Sunny Chapel, Haig Bozigian, Rosa Luo
- T39. Effects of Valbenazine on AIMS Response in Patients With Tardive Dyskinesia: Analyses by Psychiatric Diagnosis Subgroups**
 Khodayar Farahmand, Neurocrine Biosciences, Inc.
 Roger S. McIntyre, Christoph U. Correll, Khodayar Farahmand*, Joshua Burke, Scott Siegert

 = New Investigator Awardee ***** = Pharmaceutical Pipeline Presentation

- T40. The Effect of Treatment Expectation Across Different Conditions and on Drug Efficacy**
Jonathan Dang, Cedars-Sinai Medical Center
Jonathan Dang*, Waguih IsHak, Brigitte Vanle
- T41. Is There a Relationship Between Nicotine Dependence and Withdrawal With Current and Past Diagnosis of Anxiety and Depressive Disorders?**
Ahmad Hameed, Penn State College of Medicine
Ahmad Hameed*, Susan Valdheer, Emily Wasserman, Jonathan Foulds
- * T42. MDMA-Assisted Psychotherapy for Treatment of Chronic Posttraumatic Stress Disorder (PTSD): Findings From Phase 2 Clinical Research Trials**
Allison Feduccia, MAPS Public Benefit Corporation
Allison Feduccia*, Lisa Jerome, Michael Mithoefer, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin
- T43. A Randomized Clinical Trial Using Auditory-Based Computerized Cognitive Training in Patients With Chronic Schizophrenia in Residential Care: Interaction of Anticholinergic Burden on Treatment Effects**
Yash Joshi, University of California, San Diego
Yash Joshi*, Michael Thomas, Andrew Bismark, Emily Treichler, Melissa Tarasenko, John Nungaray, Lauren Cardoso, Juan Molina, Kristine Tiernan, Neal Swerdlow, Gregory Light
- T44. Does Culture Affect the Severity of Negative Symptoms in Schizophrenia?**
David Daniel, Bracket Global, LLC
David Daniel*, Alan Kott
- T45. Exploring the Utility of Machine Learning for Predicting Within-PANSS Errors in Schizophrenia Clinical Trials Data**
Alan Kott, Bracket Global, LLC
Alan Kott*, David Daniel
- 🏆 T46. Psychopharmacology and Prodromal Psychosis: Prescribing Patterns and Pharmacological Predictors in a Clinical Population With Attenuated Psychosis Syndrome**
Zachary Zuschlag, James A. Haley Veterans Hospital
Zachary Zuschlag*, Susan Schultz



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

- T47. Long-Term Effect of Brexpiprazole on Selected Items Affecting Social Functioning and Quality of Life in Early-Episode Patients: Results From a Post-Hoc Analysis in Patients With Schizophrenia**
Catherine Weiss, Otsuka Pharmaceutical Development & Commercialization, Inc.
Catherine Weiss*, Peter Zhang, Stine R. Meehan, Ross A. Baker
- T48. Genetic and Metabolite Variability in Folate Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia on Atypical Antipsychotics**
Kristen Ward, University of Michigan
Kristen Ward*, A. Zarina Kraal, Larisa Yeomans, Cora McHugh, Alla Karnovsky, Kathleen Stringer, Vicki Ellingrod
- T49. A Long-Term Open-Label, Rollover Phase 3b Study of Valbenazine for Tardive Dyskinesia**
Jean-Pierre Lindenmayer, New York University
Jean-Pierre Lindenmayer*, Cherian Verghese, Stephen R. Marder, Joshua Burke, Roland Jiminez, Scott Siegert, Grace S. Liang, Christopher O'Brien
- T50. Effects of Brexpiprazole on Long-Term Personal and Social Functioning in Schizophrenia**
Stine Meehan, H. Lundbeck A/S
Stine Meehan*, Peter Zhang, Mary Hobart, Catherine Weiss
- T51. SUBMISSION WITHDRAWN**
- T52. Aripiprazole Lauroxil NanoCrystal® Dispersion: A Potential 1-Day Initiation Regimen for Long-Acting Aripiprazole Lauroxil**
David Walling, CNS Network, LLC
David Walling*, Marjie Hard, Angela Wehr, Yangchun Du, Peter Weiden, Lisa von Moltke
- T53. A Phase II, Randomized, Double-Blind Study of ALKS 3831 in Schizophrenia and Co-Occurring Alcohol Use Disorder**
Bernard Silverman, Alkermes, Inc.
Mary Brunette, Christoph Correll, Stephanie O'Malley, Bernard Silverman*, Adam Simmons, Ying Jiang, Lauren DiPetrillo, David McDonnell, Leslie Citrome, Alan Green



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- T54. A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate**
Kimberly Vanover, Intra-Cellular Therapies, Inc.
Kimberly Vanover*, Robert E. Davis, Alex Dmitrienko, Michal Weingart, Philip D. Harvey
- T55. A Proof-Of-Mechanism Study of the PDE10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms Probing Reward Functions With Imaging and Behavioral Approaches**
Daniel Umbricht, F. Hoffmann-La Roche Ltd
Daniel Umbricht*, Jürgen Dukart, Markus Abt, Paul Tamburri, Chris Chatham, Michael Frank, Anne Collins, David Walling, Rick Mofsen, Daniel Gruener, Lev Gertsik, Jeff Sevigny
- T56. Real Life Assessment of Abilify Maintena (ReLiAM): Final Analysis From a Canadian Naturalistic Study of Aripiprazole Long-Acting Injectable in Patients With Schizophrenia**
Jean Proulx, Lundbeck Canada
Oluruntoba Oluboka, Joanna Bougie, Jean Proulx*
- T57. Sustained Remission and Symptomatic Stability Among Patients With Schizophrenia Receiving Aripiprazole Once-Monthly in a 52-Week, Open-Label, Maintenance Study**
Heather Fitzgerald, Lundbeck
Timothy Peters-Strickland, Na Jin, Heather Fitzgerald*, Pedro Such
- T58. The Neuroimaging Effects of Single-Session tDCS on Brain Regions Implicated in Impaired Insight in Schizophrenia**
Fernando Caravaggio, Centre for Addiction and Mental Health
Fernando Caravaggio*, Julia Kim, Eric Plitman, Shinichiro Nakajima, Youssef Alshehri, Yusuke Iwata, Jun Ku Chung, Mahesh Menon, Daniel Blumberger, Bruce Pollock, Gary Remington, Vincenzo De Luca, Ariel Graff-Guerrero, Philip Gerretsen
- T59. Real-World Patient Experience With Treatment-Emergent Sexual Dysfunction (TESD) in Depression**
Paula Jacobsen, Takeda Development Center Americas, Inc.
Paula Jacobsen*, Eileen Mack Thorley, Chris Curran, Emil Chiauuzzi



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

T60. Bremelanotide for Hypoactive Sexual Desire Disorder in the RECONNECT Study: Analysis of Co-Primary Endpoints According to Baseline FSFI Total Scores

Anita Clayton, University of Virginia
 Anita Clayton*, Sheryl Kingsberg, Leonard DeRogatis, James Simon,
 Robert Jordan, Johna Lucas

 **T61. Suicidal Ideation Among Newly Admitted Nursing Home Residents in the U.S.**

Christine Ulbricht, University of Massachusetts Medical School
 Christine Ulbricht*, Jacob Hunnicutt, Yiyang Yuan, Kate Lapane

T62. Does Citalopram Increase the Frequency of Up-Switches of Impulsive Suicidality in a Subject With Impulse Attack Suicidality Disorder? A Case Study

David Sheehan, University of South Florida College of Medicine
 David Sheehan*, Jennifer M. Giddens

 **T63. Sleep Disturbances Predict Suicidal Ideation During and After Inpatient Treatment**

Michelle Patriquin, Baylor College of Medicine
 Michelle Patriquin*, Elizabeth Hartwig, Katrina Rufino, Cara Palmer,
 Candice Alfano, Sanjay Mathew

T64. The Graphic Display of Quantitative Suicidality Data: S-Plots



Jennifer Giddens, University of South Florida
 Jennifer Giddens*, David V. Sheehan

T65. Rationale and Design of Four Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Extended-Release Viloxazine (SPN-812) for ADHD in Children and Adolescents

Janet Johnson, Supernus Pharmaceuticals, Inc.
 Janet Johnson, Toyin Adewole, Marina Lowen*, Tesfaye Liranso, Azmi Nasser

T66. Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders: Ready for Phase 2 Clinical Trials in Tobacco and Cocaine Use Disorders

Michael Detke, Indiana University School of Medicine
 Michael Detke*, Gary Connor, Julie Straub, Ann Robbins, Carol Gloff,
 Nicholas Goeders

 = New Investigator Awardee  = Pharmaceutical Pipeline Presentation

- T67. Long-Term Safety of Intranasal Esketamine Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Phase 3, Open-Label, Safety and Efficacy Study (SUSTAIN-2)**
Ewa Wajs, Janssen, Pharmaceutical Companies of Johnson & Johnson
Ewa Wajs*, Leah Aluisio, Randall Morrison, Ella Daly, Rosanne Lane, Pilar Lim, Richard Holder, Gerard Sanacora, Allan H Young, Siegfried Kasper, Ahmad Hatim Sulaiman, Cheng-Ta Li, Jong-Woo Paik, Hussein Manji, David Hough, Wayne Drevets, Jaskaran Singh
- T68. Exploring Femicide Statistics in Latin America - Ecuador**
Jorge Gonzalez Crow, Catholic University of Guataquil Ecuador
Victoria Valdez, Jorge Gonzalez Crow*, Melissa Dueñas, Jorge Villacreses, Erick Torres, Karyn Zambrano
- T69. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression**
Rachel Ochs-Ross, Janssen Research and Development, LLC
Rachel Ochs-Ross*, Ella Daly, Yun Zhang, Rosanne Lane, Pilar Lim, Karen Foster, David Hough, Hussein Maji, Wayne Drevets, Gerard Sanacora, Caleb Adler, Rupert McShane, Raphaël Gaillard, Jaskaran Singh



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

Aaronson, Scott	17, 70	Bitter, Istvan	83
Abdallah, Chadi	84	Bixler, Edward	84
Abt, Markus	80, 92	Blier, Pierre	83
Achtyes, Eric	85	Blom, Thomas	85
Adewole, Toyin	93	Blumberger, Daniel	92
Adler, Caleb	94	Bodnik, J. Alexander	78
Adler, Lenard A.	82	Bohn, Laura	35
Agarwal, Sri Mahavir	80	Bond, David	74
Ahle, Gabriella	77	Bougie, Joanna	78, 92
Ahmed, Mohammed	17	Bowker, Marguerite	76
Akeju-Johnson, Oluwaseun	87	Bozhdaraj, Durim	73
Akiki, Teddy	7, 84	Bozigian, Haig	89
Alam, Danesh	39, 84	Breier, Alan	32
Alfano, Candice	93	Brin, Mitchell	77
Alphs, Larry	53, 76, 87	Brittain, Scott	74
Alshehri, Youssef	92	Brown, Lisa C.	87
Althof, Stanley	82	Brunette, Mary	85, 91
Aluisio, Leah	94	Bugarski-Kirola, Dragana	74
Amado, Darlene	69	Burch, Daniel	62
Amatniek, Joan	74, 85	Burdick, Katherine E.	75, 86
Amos, Tony	80	Burger, Francisco	80
Anand, Amit	17, 50	Burgess, Frederick	76
Anfray, Caroline	69	Burke, Joshua	89, 91
Armstrong, Krista	89	Burkhouse, Katie	7, 75
Asher, Gary	88	Busner, Joan	76
Atkins, Alexandra	41	Calabrese, Joseph	20, 85, 86
Avenevoli, Shelli	12, 52, 61	Calvo, Ana	76
Bahekar, Pratik	17, 41	Cameron, Catherine	74
Bailey, Genie	35	Canuso, Carla	52
Bajbouj, Malek	77	Cao, Charlie	88
Baker, Ross A.	16, 37, 52, 53, 73, 74, 85, 88, 89, 91	Caravaggio, Fernando	81, 92
Ballard, Clive	42	Cardoso, Lauren	90
Barag, Jessica	89	Carhart-Harris, Robin	36
Barbeito, Sara	76	Carmody, Thomas	87
Bardsley, Ryan	82	Castro, Manuel	88
Barnett, Jennifer	75, 88	Chakravarty, Mallar	81
Bauer, Isabelle	17, 41	Chapel, Sunny	89
Baune, Bernhard	81	Chatham, Chris	80, 92
Becerra, Juan Antonio	76	Chen, Maxine	74, 85
Beckwith, Travis	85	Chen, Wen-Hung	64
Bender, Randall	81	Chengappa, Roy	32, 53
Bernanke, Joel	87	Cheung, Joey	87
Biederman, Joseph	34	Chiauszi, Emil	92
Biernacka, Joanna	73, 74	Chien, Stephanie	75
Bigio, Betty	73	Chintoh, Araba	7, 80
Bismark, Andrew	90	Chitayat, David	82, 85
		Choi, Doo-Sup	73
		Chokka, Pratap	78

Chung, Jun Ku	81, 92	Davies, Paige E.	87
Church, Taylor	78, 82, 85	Davis, Lori	13, 16, 19, 61, 65
Citrome, Leslie	20, 38, 53, 83, 91	Davis, Michael	19, 27, 37, 64
Clark, Crystal	17	Davis, Michelle	88
Clark, Scott	81	Davis, Robert E.	81, 92
Claxton, Amy	77, 78, 80	Davis, Tigwa	85
Clayton, Anita	15, 16, 61, 63, 82, 93	Deal, Allison	75
Clerie, Jennifer	85	Debattista, Charles	86
Clinch, Thomas	84	Dechairo, Bryan M.	87
Coccaro, Emil	76	Deckersbach, Thilo	87
Coffey, Alissa	84	DelBello, Melissa	75
Coffey, Barbara	34	Deligiannidis, Kristina	20
Cohen, Lawrence	17	De Luca, Vincenzo	92
Cohen, Lee	16, 63, 78, 82, 85	Deng, Ling	75, 79, 81
Colby, Colin	74	Deng, Zhi-De	7, 87
Cole, Ashley	80	de Oliveira Diniz, Breno Satler	84
Collins, Anne	80, 92	DeRogatis, Leonard	82, 93
Collins, Katherine	77	Detke, Michael	93
Colquhoun, Helen	76	DiBernardo, Allitia	76, 87
Comer, Sandra	9, 35, 60	Dickinson, Nancy	64
Connor, Gary	93	DiClemente, Guillermo	80
Cooper, Crystal	33	DiPetrillo, Lauren	91
Cooper, Kimberly	77, 87	Dirks, Bryan	16, 74
Cooper, Owen	81	Divacka, Ilona	83
Cormack, Francesca	75, 88	Dmitrienko, Alex	81, 92
Correll, Christoph U.	19, 20, 89, 91	Doblin, Rick	90
Costi, Sara	77	Doherty, James	76
Crippa, Jose	79	Domakonda, Mirjana	37, 52
Crison, Lynn	17	Drevets, Wayne C.	77, 83, 94
Crow, Jorge Gonzalez	94	Dries, Jean	76
Crystal, Roger	35	Drouillard, Amy	78
Cubala, Wieslaw	83	Du, Yangchun	80, 91
Cuellar-Barboza, Alfredo	74	Duca, Anna	83
Culpepper, Larry	17	Dueñas, Melissa	94
Curran, Chris	92	Duffy, Ruth A.	88
Cusin, Cristina	17, 40, 77, 86, 87	Dukart, Jürgen	80, 92
Cutler, Andrew J.	79	Durgam, Suresh	77
da Costa, Sabrina Correa	7, 84	Duvold, Laëtitia Bouérat	81
Dale, Roman	51	Earley, Willie	41
Daly, Ella	39, 77, 83, 94	Ehrich, Elliot	16, 77
Dang, Jonathan	90	Eliassen, James	85
Daniel, David	90	Ellingrod, Vicki	91
Daskalakis, Zafiris	70	Emerson, Amy	90
Davidson, Michael	39, 80	Engeland, Christopher G.	84
		Engelhardt, Nina	80
		Epstein, Irvin	74
		Eramo, Anna	88

Eriksson, Hans	88	Gloff, Carol	93
Evans, Jennifer	7, 40	Goddard, Andrew	73
Fagiolini, Andrea	83	Goeders, Nicholas	93
Falk, Daniel	32	Goez-Mogollon, Lina	85
Farahmand, Khodayar	89	Goldberg, Joseph	20
Farchione, Tiffany R.	8, 14, 16, 19, 27, 47, 54, 71	Goldman, Robert	74, 75, 79, 81, 82
Fava, Maurizio	18, 33, 68, 77, 78, 86	Goodman, Wayne	86
Feduccia, Allison	38, 90	Gorman, John	76
Fehnert, Ben	88	Graff-Guerrero, Ariel	81, 92
Felicione, Julia M.	87	Greaney, Jody	84
Fernandez-Castilla, Belén	76	Green, Mallik	81
Fervaha, Gagan	81	Green, Teresa	79
Findling, Robert	54	Green, Alan	91
Fine, Alexa	74	Greenberg, Benjamin	76
Fischer, Bernard	64	Greenberg, Tsafrir	33
Fishman, Marc	84	Greer, Tracy	87
Fitzgerald, Heather	74, 92	Grilo, Carlos	41
Fitzgerald, Kate	75	Grosz, Daniel	76
Fleck, David	85	Gruener, Daniel	80, 92
Flynn, Martina	78, 86	Guerdjikova, Anna I.	85
Forma, Felicia	79, 85	Gunduz-Bruce, Handan	76
Foster, Karen	94	Gutierrez, Nichole	89
Fotinos, Kathryn	74	Gwin, Keva	88
Foulds, Jonathan	79, 90	Hahn, Margaret	80
Fowler, Corey	89	Halladay, Christopher	76
Francois, Clement	88	Hambro, Benjamin	78
Frank, Michael	80, 92	Hameed, Ahmad	18, 79, 90
Fredericks, Doral	74	Hameed, Usman	18, 79
Freeman, Marlene	15, 20, 53, 59, 63, 77, 78, 82, 85, 86	Han, Ming-Hu	77
Friedman, Allyson	77	Hand, Holly	78
Fried, Ronna	34	Hanina, Adam	37, 82
Frye, Mark	73, 74	Hard, Marjie	91
Gadad, Bharathi	7, 87	Harkavy-Friedman, Jill	52, 89
Gaillard, Raphaël	94	Haroon, Ebrahim	18
Gannon, Jessica	7, 32, 79	Harris, Laurn	82
Garcia, Rebekah	73	Hartry, Anne	81
Gartlehner, Gerald	88	Hartwig, Elizabeth	93
Gaynes, Bradley	88	Harvey, Philip D.	75, 81, 92
George, Vinu	88	Hasin, Deborah	31
Gerretsen, Philip	6, 48, 81, 92	Hefting, Nanco	88
Gertsik, Lev	80, 92	Hellerstein, David	87
Geske, Jennifer	73	Hendrickson, Rebecca	7, 86
Giddens, Jennifer M.	69, 93	Hendry, Patrick	89
Glick, Ira	50, 79	Henry, Mellissa	76
		Henry, Michael	18
		Hernández-Díaz, Sonia	78, 82, 85
		Herschman, Philip	84

Hertel, Peter	85	Kane, John	20, 37, 49, 62
Ho, Man Choi (Ada)	73	Kanes, Stephen	39, 43, 76
Hobart, Mary	88, 91	Karayumak, Suheyra C.	87
Hochadel, Thomas	86	Karki, Sharon	73
Hoepfner, Bettina	77, 78, 86	Karnovsky, Alla	91
Hoffman, Valerie	88	Karp, Jordan	51
Holder, Richard	94	Karpouzian, Tatiana	81
Hoover, Ronald L.	13, 61	Kashambwa, Rutendo	78
Hopkins, Seth C.	79, 82	Kasper, Siegfried	94
Hopyan, Talar	36	Katzman, Martin	74
Horohonich, Steven	86	Katz, Rachel	86
Hough, David	76, 77, 83, 87, 94	Kautz, Marin	77
Hsu, Jay	74, 82	Kay, Gary	78, 86
Hudson, James	79	Keefe, Richard	86
Hufford, Michael	35	Kennedy, James L.	87
Hunnicutt, Jacob	93	Kennon, Kellie	86
Ionescu, Dawn	37	Ketter, Terence	70
Iosifescu, Dan V.	77, 86	Khan, Anzalee	53, 54
IsHak, Waguih	90	Khoury, Antoine El	80
Ivkovic, Jelena	88	Kim, Jean	52, 64
Iwata, Yusuke	81, 92	Kim, Julia	81, 92
Jacobsen, Paula	82, 92	Kim, Seung	79
James, Lynn	77	King, James	88
Jamieson, Carol	87	Kingsberg, Sheryl	82, 93
Jane, Shofer	86	Kinon, Bruce	19, 27, 49
Janik, Adam	83	Kious, Brent	36
Jerome, Lisa	90	Kirschner, Jason	76
Jha, Manish	33, 87	Kitay, Brandon	86
Jia, Yun-Fang	73	Kleinman, Leah	81
Jiang, Ying	91	Koblan, Kenneth S.	79, 82
Jiminez, Roland	91	Kocsis, James	73
Jin, Na	74, 85, 92	Kollins, Scott H.	82
Johe, Karl	39, 78, 86	Kong, Lan	84
Johnson, Brian R.	74, 85	Koola, Maju	82
Johnson, Janet	93	Kornstein, Susan	16, 18, 63, 77
Jonas, Jeffrey	76	Kott, Alan	76, 90
Jones, Amanda	86	Kraal, A. Zarina	91
Jones, Richard	76	Kramer, Luke	89
Jordan, Robert	82, 93	Krishnamurthy, Venkatesh	84
Joshi, Gagan	34	Krystal, Andrew	38, 86
Joshi, Yash	7, 48, 90	Kubicki, Marek R.	87
Jovic, Sofija	69	Kumar, Santosh	86
Judge, Heidi	77	Kupfer, David J.	16
Juneau, Paul	80	Lane, Rosanne	76, 77, 83, 94
Kadriu, Bashkim	69	Lane, Scott D.	84
Kalaria, Shamir	42, 79	Lapane, Kate	93
Kamath, Jayesh	41	Lauriello, John	80
		Lee, Francis	73

Leggio, Lorenzo	11, 60	Mathew, Sanjay	18, 50, 77, 79, 86, 88, 93
Lenderking, William R.	81	Mathis, Mitchell	14, 64, 71
Li, Cheng-Ta	94	Mattes, Jeffrey	89
Li, Ella	76	Matyas, Gary	35
Li, Haihong	76	Mayberg, Helen	10, 60
Li, Huafang	80	Mazariegos, David	73
Liang, Grace S.	91	Mazzone, Erica	77
Light, Gregory	90	McCue, Maggie	88
Li, Honglan	83	McDonnell, David	91
Lijffijt, Marijn	88	McElheny, Sara	78, 82, 85
Lim, Pilar	76, 77, 83, 94	McElroy, Susan	74, 79, 85
Lindenmayer, Jean-Pierre	53, 54, 91	McEwen, Bruce	73
Lindsten, Annika	88	McGonigal, Patrick	82
Liranso, Tesfaye	74, 93	McHugh, Cora	91
Lisanby, Sarah	86	McIntyre, Roger S.	86, 89
Lisotto, Maria	18	McNamara, Cynthia	80
Litten, Raye	16	McShane, Rupert	94
Liu, Jeen	77	Meehan, Stine R.	81, 88, 91
Li, Xiang	83	Mehta, Mehul	54
Loebel, Antony	16, 74, 75, 79, 81, 82	Meltzer-Brody, Samantha	76
Loewen, Gordon	89	Meltzer, Herbert	81
Lowen, Marina	74, 93	Memisoglu, Asli	77, 78
Lucas, Johna	82, 93	Menon, Mahesh	92
Lum, Arlene	77	Meyer, Roger	84
Luo, Rosa	89	Mickey, Brian	36
Luthringer, Remy	80	Millard, Steven	86
Lyu, Jihun	78	Miller, Brian	75, 79
Maayan, Lawrence	40	Milovan, Denise	36
Machado-Vieira, Rodrigo	69	Milrod, Barbara	18
MacKenzie, Nicole	80	Mithoefer, Michael	90
Madera, Jessica J.	73, 74, 85	Mofsen, Rick	80, 92
Mago, Rajnish	62	Mohite, Satyajit	73
Majd, Marzieh	84	Molero, Patricio	77, 83
Maji, Hussein	94	Molina, Juan	90
Makhlouf, Ahmed	78	Monk, Christopher	75
Mamo, David	81	Montoya, Iván	12, 16, 19, 27, 60
Manjelienskaia, Janna	80	Moreno, Francisco	16, 18
Manji, Hussein	77, 83, 94	Morin, Lynn	19, 27
Mann, J. John	10, 60	Morris, Laurel	77
Mantua, Valentina	8, 14, 47, 71	Morrison, Randall	94
Mao, Yongcai	75	Morrissey, Judy	76
Mar, Wanna	81	Moussaoui, Driss	79
Marder, Stephen R.	20, 32, 49, 91	Mucha, Lisa	88
Mariano, Timothy	18, 42, 76	Mulsant, Benoit H.	81
Martin, Jacob	82	Muniz, Javier	64
Martin, William	68, 77, 78		

Murrough, James	36, 38, 51, 73, 77, 86	Park, Lawrence	69
Nakajima, Shinichiro	81, 92	Pasternak, Ofer	87
Nakamura, Zev	75	Pathak, Sanjeev	77, 78, 79
Nangia, Narinder	79	Patriquin, Michelle	7, 93
Nasca, Carla	7, 73	Payne, Jennifer	63
Nasser, Azmi	93	Perez, Eli	89
Nations, Kari	37	Peterson, Bradley	87
Navia, Bradford	79	Peters-Strickland, Timothy	38, 89, 92
Nemeroff, Charles	73	Peyda, Stefan	87
Nestler, Eric	77	Phan, K. Luan	75
Newcomer, John	15, 20, 47, 62, 71	Phan, Stephanie	7, 89
Newport, Donald J.	73	Phillips, Katharine	19, 20, 37, 83
Newport, Graham	73	Pikalov, Andrei	74, 75, 81, 82
Nia, Anahita Bassir	17	Pirner, Mark	84
Niederehe, George	51	Pizzagalli, Diego	77, 86
Nielsen, Jace	89	Plitman, Eric	81, 92
Nomikos, George	82	Pollack, Mark	17, 18
Nugent, Allison	70	Pollock, Bruce	81, 92
Nunes, Edward	35	Popova, Vanina	38, 77, 87
Nungaray, John	90	Port, John	73
Nurnberger, John	86	Posner, Jonathan	87
Oakley, Margot	76	Post, Robert	50, 70
O'Brien, Brittany	88	Potter, William	50, 86
O'Brien, Christopher	91	Powers, Albert	7, 40
Ochs-Ross, Rachel	76, 94	Pratt, Sarah	85
O'Gorman, Cedric	86	Price, Barbara	73
Okusaga, Olaoluwa	73	Prieto, Miguel	74
Olagunju, Andrew	7, 81	Proctor, Steven	7, 84
Oluboka, Oloruntoba	92	Proulx, Jean	78, 92
O'Malley, Stephanie	16, 31, 91	Radhakrishnan, Rajiv	18, 40
Opler, Mark	54	Raj, Prithvi	87
Opperman, Michael	85	Randall, Penny	62
Oskooilar, Nader	76	Rapaport, Mark H.	15, 17, 20, 27, 36, 65, 70
Ostroff, Robert	86	Rasgon, Natalie	73
Ottinger, Jocelyn	85	Raskind, Murray	86
Owen, James	74	Reilly, James	81
Owens, Mark S.	75	Remington, Gary	80, 81, 92
Paik, Jong-Woo	94	Revicki, Dennis	82
Palmer, Cara	93	Richardville, Kyle	79
Palumbo, Joseph	16	Rising, Kate	88
Panagopoulos, Ellie	88	Robbins, Ann	93
Pani, Luca	16, 52	Rooney, Mary	37
Papakostas, George	62, 68, 77, 78, 86	Rosenberg, David	76
Parikh, Sagar V.	88	Rosenstein, Donald	75
Park, Eliza	75	Rostain, Anthony	62
		Rubinow, David	76
		Rubio, Jose	49

Rudorfer, Matthew	37	South, Charles	7, 42
Ruetsch, Charles	85	Stahl, Stephen	75
Rufino, Katrina	93	Staner, Corinne	80
Russo, Priscilla	78	Stanford, Arielle D.	77, 78, 79
Saillard, Jelena	89	Stankovic, Srdjan	74
Sajatovic, Martha	37, 70	Starr, Lynn	76, 87
Salisbury, Dean	32	Stein, Michael	76
Salloum, Naji	7, 86	Sternat, Tia	74
Saltz, Samantha	73	Stilwell, Kellen	85
Sanacora, Gerard	50, 77, 86, 94	Stocks, Jane	81
Sanchez-Gutierrez, Teresa	76	Stone, Marc	42, 79
Sankoh, Abdul	76	Straub, Julie	93
Saoud, Jay	80	Stringer, Kathleen	91
Sarampote, Christopher	15, 27	Such, Pedro	73, 74, 85, 92
Sarkey, Sara	88	Sulaiman, Ahmad Hatim	94
Satyasi, Savitha Kumari	73	Sullivan, Gregory	52
Saunders, Erika	18, 84	Suppes, Trisha	20, 78
Saylor, Keith	74	Swann, Alan C.	88
Schooler, Nina R.	19, 27	Swartz, Holly A.	15, 17, 19, 27, 61
Schork, Nicholas	86	Swordlow, Neal	90
Schultz, Susan	90	Swetlik, Carol	82
Schuster, Jennifer	88	Sydnor, Valerie J.	87
Scott, Shamecca	18	Szabo, Steven	86
Setnik, Beatrice	35, 79	Szegedi, Armin	77
Sevigny, Jeff	80, 92	Tabuteau, Herriot	86
Shafner, Laura	82	Taliaz, Dekel	89
Shalhoub, Huda	81	Tallman, Maxwell	85
Sharma, Shiva	73	Tamburri, Paul	80, 92
Shawi, May	76, 87	Tan, Aaron	77
Shea, Thomas	75	Tandon, Rajiv	81
Sheehan, David V.	69, 93	Tanner, Julie-Anne	87
Shelton, Richard	77, 83	Taptiklis, Nick	75, 88
Shen, Yifeng	80	Tarasenko, Melissa	90
Shenton, Martha E.	87	Tcheremissine, Oleg	19
Siegert, Scott	89, 91	Teigland, Christie	79
Silverman, Bernard	31, 91	Teixeira, Antonio L.	19, 84
Silverman, Samantha	76	Thase, Michael E.	20, 60, 68, 77, 78, 83
Simmons, Adam	91	Thomas, Michael	90
Simon, James	93	Thorley, Eileen Mack	92
Singh, Balwinder	74	Tiernan, Kristine	90
Singh, Jaskaran	76, 77, 83, 87, 94	Tocco, Michael	75, 81
Singh, Jatinder	84	Tong, My-Linh	76
Siu, Cynthia	75	Topping, Peter	65
Skolnick, Phil	5, 35, 48	Torres, Erick	94
Smoski, Moria	86	Toure, Juliette	64
Soares, Jair	18	Treichler, Emily	90
Sosinsky, Alexandra	78, 82, 85		

Trivedi, Madhukar	17, 20, 33, 50, 52, 68, 77, 78, 83, 86, 87	Weiss, Catherine	81, 88, 91
Tsai, Joyce	75, 82	Wells, Allison	88
Tulloch, Gabriela	74	Wells, Jesse	88
Tye, Susannah	19	Whitton, Alexis	77
Tyner, Tim	73	Whyte, Ellen	51
Ulbricht, Christine	7, 93	Wilcox, Charles	76
Umbricht, Daniel	38, 80, 92	Wilkinson, Samuel	86
Valdez, Victoria	94	Williams, Stephanie	85
Valdheer, Susan	79, 90	Wilson, Hilary	82
Van Dam, Nicholas	77	Winokur, Andrew	83
Vanle, Brigitte	90	Witkeiwitz, Katie	31
Vanover, Kimberly	81, 89, 92	Wolanski, Kristy	80
Van Schaik, Tempest	88	Wood, William	75
van't Wout-Frank, Mascha	76	Wozniak, Janet	34
Vega, Monica	73	Wynn, Jonathan	32
Veldic, Marin	73, 74	Yadav, Sanjay	84
Verghese, Cherian	91	Yavorsky, William	80
Vgontzas, Alexndros	84	Yazar-Klosinski, Berra	90
Vieta, Eduard	77	Yeomans, Larisa	91
Viguera, Adele	78, 82, 85	Yeung, Albert	78
Villacreses, Jorge	94	Youakim, James	74
Vlahiotis, Anna	80	Young, Allan H.	94
von Moltke, Lisa	91	Young, Henry	89
Voudouris, Nicholas C.	87	Young, Robert	51
Wajs, Ewa	94	Young, Sarah	73
Wakeland, Edward	87	Younis, Islam	55
Walling, David	54, 80, 91, 92	Yuan, Yiyang	93
Wang, Changning	40	Zajecka, John	83
Wang, Tao	89	Zambrano, Karyn	94
Wang, Xingmei	76	Zannas, Anthony	7, 40
Wang, Yaning	54	Zarate, Carlos A.	19, 38
Wang, Yun	87	Zhang, Doris	88
Ward, Kristen	91	Zhang, Jianping	19
Wasserman, Emily	79, 90	Zhang, Peter	73, 85, 91
Webb, Christian	33	Zhang, Yun	76, 83, 94
Webler, Ryan	86	Zhao, Cathy	89
Wehr, Angela	91	Zhong, Wei	82
Weiden, Peter	80, 91	Zhu, Hao	54
Weiner, Richard	86	Zimmerman, Mark	19, 42, 82
Weingart, Michal	81, 92	Zisook, Sidney	20
		Zorumski, Charles	76
		Zuschlag, Zachary	7, 90

FUTURE ASCP MEETINGS



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

2018 ANNUAL FALL MEETING

OCTOBER 6-7, 2018 | THE ROOSEVELT HOTEL | NEW YORK, NY

PSYCHOPHARMACOLOGY UPDATE: STATE-OF-THE-ART 2018

Fall 2018 Psychopharmacology Update: State-of-the Art Meeting October 6-7, 2018

The Roosevelt New York, New York



Fairmont
SCOTTSDALE PRINCESS



2019 ASCP Annual Meeting May 27 – 31, 2019

Fairmont Scottsdale Princess, Scottsdale, Arizona



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

www.ascpp.org

ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027

phone: 615-649-3085
fax: 888-417-3311
email: info@ascpp.org

